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1. Introduction 
1.1 Glioblastoma 
Gliomas are the most prevalent primary central nervous system (CNS) tumors and 
presumably are of glial origin [1-3]. Among all gliomas, glioblastoma, also called 
glioblastoma multiforme (GBM), is the most frequent and most devastating brain 
neoplasm. Those toward have the highest histological grade, namely grade IV, as 
classified by the World Health Organization (WHO) [4, 5]. GBM is characterized 
morphologically by hypercellularity, nuclear atypia, mitotic figures, high 
vascularization, necrosis and pseudopalisades [6]. The degree of these morphological 
features is positively correlated with the malignancy. Ninety percent of the GBM 
cases are primary or de novo glioblastoma, which are diagnosed in patients with no 
clinical history for brain tumors. Secondary glioblastoma account for the remaining 
10% which often originates from the progression of a low-grade glioma like diffuse or 
anaplastic astrocytomas [7]. Primary glioblastomas are isocitrate dehydrogenase gene 
wild-type (IDH-WT) glioblastoma with a median overall survival of 9.9-15 months, 
and secondary glioblastomas are IDH-mutant glioblastoma with an average survival 
of 24-31 months [5]. 
 
1.1.1 Glioblastoma treatment 
The complete surgical resection of GBM is virtually impossible because tumor cells 
extensively invade the surrounding brain tissue. As a consequence, for the newly 
diagnosed GBM, the treatment strategy always requires the combination of maximum 
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safe surgical debulking, radiotherapy, and chemotherapy [8-10]. The standard 
chemotherapy scheme for GBM is temozolomide (TMZ, an alkylating agent can 
induce the death of tumor cells by breaking the DNA double-strand) [9]. The 
treatment outcomes of patients who received the combined therapy of temozolomide 
and radiotherapy is significantly better than radiotherapy alone when the gene 
promoter of a DNA repair enzyme MGMT (O6-methylguanine-DNA 
methyltransferase) is methylated and epigenetically silenced [11]. Despite aggressive 
surgery, radiotherapy, and chemotherapy, the prognosis of GBM patients remains poor 
with a median survival of 14 to 16 months [12, 13]. Therefore, new treatment 
approaches for GBM are desperately needed. 
 
1.1.2 Genetic subtypes of glioblastoma 
To achieve a better patient stratification, researchers have investigated genomic 
expression alteration from the Cancer Genome Atlas (TCGA) dataset and classified 
glioblastoma into four subtypes which were named classical, proneural, mesenchymal 
and neural [14]. The neural subtype is less well defined and more inclined to be 
considered as a potential artifact now [15]. The classical subtype is characterized by 
the upregulation of the EGFR (epidermal growth factor receptor) gene expression and 
the loss of PTEN (phosphatase and tensin homolog) and CDKN2A (cyclin-dependent 
kinase Inhibitor 2A) gene loci. Alterations in the TP53 (one of the most frequently 
mutated genes in glioblastoma) are nearly absent in this genetic subtype [14, 16]. 
Unlike the classical GBM, the proneural tumors are marked by mutations in the TP53 
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(54%) and IDH1 (isocitrate dehydrogenase 1; 30%) genes, and by overexpression of 
the PDGFRA (platelet-derived growth factor receptor-α) gene [14, 16]. The 
mesenchymal GBM subtype has frequent inactivation of three tumor suppressor genes: 
the NF1 (Neurofibromatosis type 1; 37%), TP53 (32%), and PTEN (32%) genes [14, 
16]. The genetic stratification of glioblastoma provides the possibility to establish 
more personalized therapies and improve the clinical efficacy. 
Glioblastoma stem cells (GSCs) are a subset of cells with the ability of self-renewal 
and multi-lineage differentiation in the tumor microenvironment and are also the main 
cause of the chemoradiotherapy resistance and tumor recurrence [17, 18]. Isolation 
and purification of GSCs from GBM patients are important to investigate more 
specific targeting therapies for these cells [19, 20]. Furthermore, the neural precursor 
cells (NPCs) in the subventricular zone (SVZ) of mice can be isolated and 
manipulated to model different genetic subtypes of GSCs by altering genomic 
expression in these cells: for instance, the mouse glioblastoma cell line p53
KO
PDGFB 
GSC is a good model of the proneural GBM subtype by knocking out TP53 and 
overexpression of PDGFB in mouse NPCs [21]. 
 
1.1.3 Anti-angiogenic therapy for glioblastoma 
Judah Folkman first proposed the hypothesis in the early 1970s that angiogenesis is 
required for the expansion of tumor spheroids beyond a diameter of 2-3 mm at which 
point the oxygen/nutrient supplies and waste products removal become difficult 
without the vasculature [22]. Since then tumor angiogenesis has been studied 
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intensively and is now known as one of the hallmarks of cancer [23, 24]. The 
development of the vasculature is a vital process during embryogenesis including 
vasculogenesis (the generation of new endothelial cells from progenitor cells and tube 
formation by these endothelial cells) and angiogenesis (the process of new vessels 
sprouting from existing ones) [25-27]. Once established, the vasculature becomes 
quiescent. In the adult, angiogenesis is controlled by pro-angiogenic and 
anti-angiogenic regulators in dynamic homeostasis and only transiently turned on 
during physiological processes such as wound healing and the female reproductive 
cycle. However, during tumor progression, the homeostasis is disrupted and an 
“angiogenic switch” is turned on activating continuous sprouting of new vessels to 
support expanding neoplastic growth [24-26]. The most studied angiogenic inducer is 
vascular endothelial growth factor (VEGF) which is highly expressed by cancer cells 
in hypoxic condition together with hypoxia-inducible factor (HIF) to trigger tumor 
angiogenesis [28-30]. Three subtypes of VEGF receptor (VEGFR1, VEGFR2, and 
VEGFR3) have been identified [31]. Among them, VEGFR2 is the major one 
expressed on endothelial cells for the angiogenic response [32]. Consequently, VEGF 
or VEGFR targeting is considered a promising therapy for the cancer treatment, and 
inhibitors of VEGF or VEGFR have been included as the potential anti-cancer agent 
in clinical trials [33, 34]. Bevacizumab (a humanized antibody targeting VEGFA) has 
become the first anti-angiogenic agent granted the approval of United States Food and 
Drug Administration (FDA) in 2004 for the treatment of colorectal cancer [35]. 
GBM is a highly vascularized brain tumor with VEGF abundantly expressed around 
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the hypoxic or necrotic area [36, 37]. This prompted the development of anti-VEGF 
or anti-VEGFR therapies for GBM [37-40]. Bevacizumab was approved by FDA 
recently (full approval in 2017) for the treatment of recurrent glioblastoma but failed 
to get the approval of the European Medicines Agency (EMA) [41-43]. Different 
findings were displayed in various clinical studies for recurrent GBM. A phase II 
clinical trial (BELOB) showed that bevacizumab plus lomustine (an alkylating 
nitrosourea compound used in chemotherapy) could improve both the 6-month 
progression-free survival (PFS) and 9-month overall survival (OS) of recurrent GBM 
patients in comparison to either agent alone [44, 45]. Nevertheless, a subsequent 
phase III study published in 2017 (EORTC 26101) only validated the benefits of 
bevacizumab plus lomustine treatment on PFS but not on OS [46]. For newly 
diagnosed GBM patients, a phase II clinical trial and two randomized phase III 
clinical studies (AVAglio and RTOG 0825) reported that bevacizumab combined with 
temozolomide chemoradiotherapy did not show an improved OS in comparison to 
standard chemoradiotherapy, but only improved PFS [47-50]. Studies of other 
anti-angiogenic agents for glioblastoma such as cilengitide (a synthesized cyclic 
pentapeptide targeting αv integrins) and cediranib (a tyrosine kinase inhibitor which 
blocks all VEGFRs) showed similar outcomes like the trials for bevacizumab [37, 51, 
52]. 
While tumor biology of GBM underscores the potential of anti-angiogenic therapy, 
the results of prior studies remain disappointing and underscore the importance of 
investigating tumor resistance mechanisms to anti-VEGF/VEGFR agents. The 
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activation or upregulation of alternative pathways for angiogenesis could be one of 
the prime causes of the resistance to anti-VEGF/VEGFR therapies [53-55]. Besides 
VEGF, there are several additional regulatory factors such as basic fibroblast growth 
factor (bFGF), angiopoietin 2 (ang-2), placenta growth factor (PIGF), stromal 
cell-derived factor 1 (SDF-1/CXCL12), and also apelin that are participating in tumor 
angiogenesis and upregulated (as compared to the tumor-free brain) in glioblastoma 
[27, 53-56]. For instance, the upregulation of bFGF and CXCL12 was found in 
progressive GBM after treatment with a pan-VEGFR tyrosine kinase inhibitor (TKI) 
AZD2171 [57]. Another possibility for the resistance to antiangiogenesis is that the 
tumor invasiveness increases after anti-VEGF/VEGFR treatment [53-55]. 
Glioblastoma is highly invasive in the brain instead of metastasizing to other organs 
outside the central nervous system [58]. Invasive GBM cells can be found as 
dispersed cells throughout the brain. These invasive cells can also co-opt preexisting 
blood vessels [30, 53]. Kunkel and colleagues found a remarkable increase of tumor 
invasiveness in a glioblastoma mouse model after the treatment of a monoclonal 
antibody (DC101) against VEGFR2 [59]. However, stratification of patients that may 
be resistant or sensitive to anti-angiogenic therapy [60-62], e.g. by post-hoc analysis 
of a clinical trial (AVAglio), suggests that IDH1 wild-type GBM patients of proneural 
subtype can profit from bevacizumab treatment [63]. Erdem-Eraslan et al. reported 
that the classical subtype showed a better response in recurrent GBM patients treated 
with bevacizumab and lomustine [64]. 
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1.2 Apelin/APLNR signaling 
O’Dowd et al. cloned a gene encoding a protein with strong homology to angiotensin 
II (Ang-II) receptor type 1 (AT1R) in 1993, and named this new receptor the 
angiotensin II receptor-like 1 or APJ [65]. The gene encoding human APJ was found 
on the long arm of chromosome 11. The receptor APJ is a seven-transmembrane G 
protein-coupled receptor (GPCR) consisting of 377 amino acids, which remained 
orphan until Tatemoto and coworkers identified its endogenous ligand (a bioactive 
peptide) from bovine stomach extract in 1998 [66]. Thus, this newly discovered 
bioactive peptide was named apelin (APJ Endogenous Ligand), and thereafter the APJ 
gene was renamed as apelin receptor (APLNR) gene. Despite the remarkable 
sequence similarity between AT1R and APLNR, Ang-II does not bind to APLNR, nor 
does apelin bind to AT1R [67]. The human apelin gene (APLN) encodes a 77 amino 
acid-long pro-apelin peptide (apelin-77) and is located on the long arm of the X 
chromosome. A pro-apelin peptide is proteolytically cleaved to several shorter 
biologically active isoforms, including apelin-36, apelin-17, apelin-16, apelin-13, and 
apelin-12 (Table 1.2) [68, 69]. A post-translational modification of apelin-13 
(pyroglutamylated apelin-13, Pyr1-apelin-13) improves resistance to enzymatic 
degradation. This represents the major apelin isoform found in human blood plasma 
[70]. Functionally, the 12 C-terminal amino acids of apelin-77 are important for the 
biological activity, and apelin-13, together with Pyr1-apelin-13, is considered to be 
the pharmacologically most active isoform [71]. 
Apelin-F13A is a mutant ligand for APLNR created in the first apelin structure studies 
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by replacing C-terminal phenylalanine (F) residue of Pyr1-apelin-13 with alanine (A) 
(Table 1.2). This peptide was first reported as an antagonist for apelin-13 due to the 
lower binding efficiency to APLNR and lower potency to trigger downstream effects 
of APLNR [72]. However, some studies found that apelin-F13A showed similar 
binding activity and internalization responses to those of Pyr1-apelin-13 for human 
APLNR in vitro [73]. Also, apelin-F13A competed with apelin-13 binding in human 
heart tissue and showed bioactivity in endothelium-denuded saphenous vein [74]. 
Therefore, it seems more appropriate to consider apelin-F13A as a competitive agonist 
for natural APLNR ligands [74, 75]. 
 
Table 1.2 Sequence of apelin peptides and analogues. 
Peptide (Human) Amino acid sequence 
Apelin-36 LVQPRGSRNGPGPWQGGRRKFRRQRPRLSHKGPMPF 
Apelin-17 KFRRQRPRLSHKGPMPF 
Apelin-16 FRRQRPRLSHKGPMPF 
Apelin-13 QRPRLSHKGPMPF 
Apelin-12 RPRLSHKGPMPF 
Pyr1-apelin-13 Pyr-RPRLSHKGPMPF-OH 
Apelin-F13A Pyr-RPRLSHKGPMPA-OH 
 
1.2.1 The physiological role of apelin/APLNR signaling 
Both in human and rodents, apelin and APLNR are expressed extensively in the CNS 
and peripheral tissues including brain, spinal cord, heart, lung, liver, kidney, ovary, 
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adipose tissues, etc. [68, 71]. Because of the structural similarity between APLNR and 
AT1R, it was investigated if apelin may regulate cardiovascular functions. Indeed, 
apelin has been shown to play a role in the cardiovascular system by increasing 
cardiac contractility and enhancing vasodilatation [68, 69]. The potent inotropic effect 
of apelin appears to be associated with PKC (Protein kinase C) activation and the 
increase of intracellular Ca
2+
 levels, while the vasodilatation seems to be the result of 
the activation of endothelial nitric oxide synthase (eNOS) depending on PI3K-Akt 
signaling induced by apelin and APLNR binding [67-69]. 
As the expression of apelin and APLNR was found in the paraventricular and 
supraoptic nucleus of the hypothalamus, studies also explored the effect of 
apelin/APLNR signaling on food intake and body fluid homeostasis [68]. However, 
the results are inconsistent: Taheri et al. found that central administration of apelin-13 
increases water intake in rats [76]; while some reported no change or a decrease of 
water intake after the treatment of apelin-13 by central injection [77, 78]. 
More importantly, many studies have determined a vital role of apelin/APLNR 
signaling in angiogenesis and embryonic development. APLNR is highly expressed 
on endothelial precursor cells in mouse and frog embryos [56, 79]. In vitro, apelin 
could increase the proliferation, migration and tube formation of human umbilical 
vein endothelial cells (HUVECs) [80] and retinal endothelial cell line (RF/6A) [81], 
and also promote the growth of mouse brain microvasculature-derived endothelial 
cells [79]. In the chick chorioallantoic membrane (CAM) assay, apelin stimulation 
showed a potent angiogenic effect with approximately equivalent vascular branch 
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points to VEGF treatment [79]. Kälin et al. found that apelin is essential for the 
angiogenic sprouting of intersomitic blood vessels of Xenopus tadpoles by conducting 
loss-of-function experiments [56]. Apelin knockout in the mouse resulted in decreased 
blood vessel diameter but did not cause obvious fatal defects in embryonic 
development [68]. An impaired myocardial contractility was observed exclusively in 
aging apelin knockout mice [82]. However, APLNR knockout led to vasculature 
malformations in mouse embryos resulting in augmented lethality. The discrepancy 
displayed in apelin knockout mice and APLNR knockout mice may be due to the 
effect of a second ligand that was identified recently and named apela (also called 
elabela or toddler) [68]. As an early endogenous ligand of the apelin receptor, apela 
may compensate for the loss of apelin in embryos of apelin knockout mice. This 
hypothesis is supported by the findings that severe heart developmental defects in 
zebrafish embryos caused by apela mutation are similar to those in APLNR knockout 
mice, which can be rescued by early ectopic expression of apelin [83, 84]. 
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Figure 1.2.1 The physiological and pathophysiological role of apelin/APLNR 
signaling. 
 
1.2.2 Apelin/APLNR in cancer 
Since tumor angiogenesis is a hallmark of cancer and apelin/APLNR signaling is 
important for angiogenesis, it is not surprising that investigators have reported that 39% 
of solid tumor samples (60/154) analyzed by RNA hybridization technology showed 
the upregulation of apelin at least 2-fold in comparison to matched non-tumor controls 
[85]. The overexpression pattern of apelin has been detected in cancers including 
hepatocellular carcinoma, lung cancer, colon cancer, oral squamous cell carcinoma, 
brain tumor, etc. [86, 87]. Lacquaniti et al. also reported significantly increased apelin 
levels in the serum of cancer patients relative to healthy controls [88]. In human 
non-small cell lung cancer (NSCLC), patients showed a significantly worse survival 
where apelin expression levels were high as compared to patients with low apelin 
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levels [89]. In animal experiments, overexpression of apelin enhanced tumor vessel 
formation and tumor growth [90]. In brain tumors, Kälin and colleagues found apelin 
and APLNR to be upregulated in the neovascular areas of GBM but no apelin and low 
levels of APLNR expression in the normal non-tumor brain [56]. They confirmed the 
overexpression pattern of apelin in GBM by interrogating the TCGA data set of GBM, 
and also found that APLN is co-expressed with other genes inducing angiogenesis 
[68]. Altogether, these findings suggest that apelin/APLNR signaling could be a 
promising target for the cancer treatment. 
 
1.2.3 Apelin/APLNR in pathological/tumor angiogenesis 
Apart from physiological processes, apelin is involved in pathological angiogenesis of 
many diseases like ischemic stroke, retinal angiogenesis diseases, myocardial 
infarction, and tumor. [91]. In particular, accumulating evidence suggests that apelin 
could be an essential regulator of tumor angiogenesis. Studies have found 
hypoxia-responsive elements in the apelin gene (APLN) sequence which allows APLN 
to be activated by HIF [79, 92-94]. And APLN was identified as a tumor-endothelial 
specific gene by comparing gene expression profiles in tumors and normal 
endothelium [95]. Also, Masiero et al. identified the APLNR gene as one of the genes 
belonging to a tumor angiogenesis core signature [96]. In the analysis of specimens 
from NSCLC patients, apelin expression was positively correlated to the density of 
microvessel [89]. In a subcutaneous xenograft mouse model for hepatocellular 
carcinoma, the treatment of apelin-F13A, a mutant ligand for APLNR, decreased the 
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tumor vessel density and inhibited tumor growth [97]. With regards to GBM, APLN 
was not only highly upregulated but also found to be co-expressed with VEGF in the 
hypoxic area, indicating that there may be a collaborative function of these two 
angiogenic factors [68]. As described above (section 1.1.3), the upregulation of 
alternative pathways of angiogenesis may be one of the leading causes of the 
unsatisfactory results in anti-VEGF/VEGFR therapy. Therefore, apelin/APLNR 
signaling could be an important angiogenic pathway resulting in the resistance to 
anti-VEGF/VEGFR treatment in GBM. 
 
1.3 Glioblastoma-associated myeloid cells and humanin peptide 
1.3.1 Glioblastoma-associated microglia/macrophages 
One major caveat for current GBM therapies is the strong support of tumor growth by 
the GBM microenvironment. The tumor stromal niche consists of parenchymal cells 
of the brain like astrocytes, endothelial cells, pericytes, microglia, and macrophages. 
[98]. Among them, microglia and macrophages accumulate abundantly in the tumor 
area, accounting for 30% of the total number of cells in the GBM tumor mass, 
whereas microglia account for only 5%-10% of the cells in normal brain tissue [99], 
indicating that the tumor-associated myeloid cells (TAMs) may play an important role 
in GBM. In fact, the infiltrating TAMs are manipulated by tumor cells in order to 
support the maintenance and progression of glioblastoma based on the results of 
recent studies [99-101]. 
Microglial cells are the major innate immune cells in the CNS and can secrete 
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inflammatory cytokines to coordinate immune responses against infection [102, 103]. 
They also engulf and digest pathogens and cellular debris by phagocytosis [104]. 
Upon loss of the blood brain barrier (BBB), monocytes can migrate into the brain, 
differentiate into macrophages and accumulate in the tumor area [101]. Glioblastoma 
cells first recruit microglia and macrophages by releasing plenty of chemoattractants 
(Figure 1.3.1) such as the macrophage colony-stimulating factor (M-CSF), monocyte 
chemoattractant protein-1 (MCP-1), and glial cell-derived neurotrophic factor (GDNF) 
[99, 101]. Then the accumulated TAMs can interact with glioblastoma cells to 
enhance tumor cell invasiveness and tumor angiogenesis [99]. Glioblastoma cells can, 
for example, produce a molecule called versican which triggers the increase of 
Toll-like receptor-2 (TLR2) expression in TAMs [105]. TLR2 upregulates the 
membrane type 1-matrix metalloproteinase (MT1-MMP), and then MT1-MMP 
cleaves the pro-form of matrix metalloprotease-2 (MMP2) and activates this enzyme 
to hydrolyze the extracellular matrix, increasing the invasion of glioblastoma cells 
(Figure 1.3.1) [99, 101]. TAMs can promote the tumor angiogenesis as well by 
synthesizing and releasing pro-angiogenic molecules (e.g. MMP-9 and tumor necrosis 
factor-α, TNF-α) [99]. Thus, TAMs, as the important cellular component of the tumor 
microenvironment, provide a promising therapeutic intervention option in 
glioblastoma that has attracted ongoing research attention. 
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Figure 1.3.1 The interactions between glioblastoma cells and tumor-associated 
myeloid cells. 
 
1.3.2 Humanin 
Humanin (HN) is a peptide identified by Hashimoto and colleagues in 2001 through 
functional expression screens of a cDNA library obtained from the intact brain region 
of an Alzheimer’s disease (AD) patient [106]. The researchers found that all the 
cDNA clones that could rescue the neuronal cells from three AD-related insults 
(mutant amyloid precursor protein, presenilin 1 and 2) shared a small (75 base-pair) 
open reading frame (sORF) encoding a 24 amino acid peptide. And overexpression of 
this sORF in neuronal cells also protected them from those AD-relevant toxicities. As 
this short peptide holds the potential for restoring the humanity of AD patient, it was 
named humanin [106, 107]. The HN ORF shows high identity with a portion of the 
mitochondrial 16S rRNA encoding region (MT-RNR2), suggesting the mitochondrial 
origin of this peptide (Figure 1.3.2) [108]. Guo et al. also cloned HN as a binding 
partner of Bax (a pro-apoptotic protein) by a yeast two-hybrid screen. The initiation of 
the apoptosis signal by the translocation of Bax from cytoplasm to mitochondria was 
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inhibited after HN bound to Bax [109]. Similarly, a third group cloned HN in the 
process of searching interactive proteins of the insulin-like growth factor-binding 
protein-3 (IGFBP-3) from another yeast two-hybrid screen. These researchers found 
that HN can also suppress apoptosis induced by IGFBP-3 [110]. 
 
 
Figure 1.3.2 Schematic diagram of the circular, double-stranded human 
mitochondrial DNA and the location of the humanin open reading frame. There 
are 22 tRNA-coding genes (circles), 2 rRNA-coding genes (blue), and 13 canonical 
protein-coding genes (other colors) in the human mitochondrial genome. The HN 
ORF (red) is located in the 16S rRNA gene. Adapted from Xiao et al. (2016) [111]. 
 
Besides the identity found between HN ORF and a part of mitochondrial 16S rRNA 
gene, the HN ORF also showed varying degrees of homology with several nuclear 
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genomic regions [106, 112]. HN is a 24 amino acid peptide if synthesized in the 
cytoplasm while it is a 21 amino acid peptide if synthesized in mitochondria due to 
the difference of codon usage pattern (Table 1.3.2), but both are biologically effective 
[109]. Hence, the origin and translational site of HN remain unclear despite of more 
evidence suggesting the mitochondrial origin [108]. To investigate the relationship of 
structure and function, researchers have performed a substitution study on each amino 
acid residue of HN. Residues 3, 7-9, 11-13, and 19 are essential for the ability of 
apoptosis protection by HN. Replacement of serine at position 14 with glycine can 
yield a potent HN analogue S14G HN or HNG, which increases the biologic potency 
by approximately 1000-fold. Phe6 and Cys8 are important for the IGFBP-3 and Bax 
binding ability respectively. As for the secretion of HN, Leu9-11, Pro19 and Val20 are 
required [111]. 
 
Table 1.3.2 Sequence of humanin peptides and analogues. 
Peptide (Human) Amino acid sequence 
Humanin (HN, cytoplasm) MAPRGFSCLLLLTSEIDLPVKRRA 
HN (mitochondria) MAPRGFSCLLLLTSEMDLPVK 
HNG MAPRGFSCLLLLTGEIDLPVKRRA 
 
1.3.3 The functions of humanin 
HN can be secreted by cells and is detectable in plasma [106, 113], thus its actions 
were considered to be mediated by specific receptors. Ying et al. identified 
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formyl-peptide receptor-like-1 (FPRL1; a seven-transmembrane G protein-coupled 
receptor) as the first HN receptor [114]. HN can compete with the 42 amino acid form 
of the b-amyloid peptide (Ab42) for binding to FPRL1 and abolish the cytotoxicity of 
Ab42 in neuroblasts. This cytoprotective effect may be accomplished by activation of 
ERK1/2 signaling after HN binds to FPRL1 as an agonist [114]. Another study found 
that HN can activate both FPRL1 and FPRL2 in Chinese hamster ovary (CHO) cells 
[115]. In addition, Nishimoto et al. demonstrated that the STAT3 (signal transducer 
and activator of transcription 3) activation is essential for the process of 
neuroprotection by HN. Thus it is possible that another type of HN receptor belongs 
to the cytokine receptor family [116]. Subsequently, they discovered a tripartite 
receptor involving gp130 (glycoprotein 130), CNTFR (ciliary neurotrophic factor 
receptor), and WSX-1 (interleukin 27 receptor, alpha subunit) as a second HN 
receptor [117]. As mentioned above, HN also interacts with intracellular molecules 
such as Bax and IGFBP-3 in addition to its functions mediated by membrane 
receptors. Within cells, HN inhibits apoptosis by interacting with these two proteins 
(Figure 1.3.3). 
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Figure 1.3.3 Humanin intracellular binding partners, membrane receptors and 
associated signaling pathways. Adapted from Lee et al. (2013) [108]. There are two 
types of humanin receptor on the cell membrane: FPRL1 and gp130/CNTFR/WSX-1 
trimetric receptor with the ERK1/2 and STAT3 signaling pathway as the downstream 
respectively. Humanin can also act in the cytoplasm by interacting with pro-apoptotic 
proteins like Bax and IGFBP-3. P, phosphorylation. 
 
HN is associated with a number of diseases such as chronic progressive external 
ophthalmoplegia (CPEO), mitochondrial encephalomyopathy with lactic acidosis and 
stroke-like episodes (MELAS), and pigmented villonodular synovitis (PVNS). A 
remarkable increase of HN expression was found in these diseases, implying that HN 
may act as a protective factor to response to cellular stress [108, 111]. On the other 
hand, HN levels appear to be negative correlated with age in rodents and human [113]. 
Furthermore, studies have reported the neuroprotective effect of HN in AD (in vitro 
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and in vivo) as well as in ischemia and reperfusion (I/R) models [111]. A gene array 
profiling data performed by our research group revealed that HN is strongly 
overexpressed in glioblastoma-associated microglia/macrophages compared with 
microglia in tumor-free brain tissue taken from epilepsy patients. This finding 
suggests that HN may play an important role in GBM and therefore could be a 
candidate for the development of new GBM therapies. 
 
1.4 Objective of the study 
As described above, apelin/APLNR signaling and humanin could both be potential 
targets for the improvement of the treatment outcomes of glioblastoma. Thus, the first 
aim of this thesis was: 
a) To investigate the impact of apelin/APLNR targeting for GBM therapy by 
assessing the survival benefit in novel GBM mouse models; 
b) To test the effect of combining APLNR targeting with established anti-angiogenic 
VEGFR2 treatment; 
c) To assess the mechanistic role of apelin/APLNR signaling in tumor angiogenesis, 
tumor cell proliferation and invasion. 
The second aim of this thesis was the study of the effect of microglia-secreted peptide 
humanin on GBM cell survival and protection against chemotherapeutic agents. 
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2. Materials 
2.1 Devices 
Table 2.1 Devices 
Equipment / Software Company  
Axiovision Rel. 4.8 / 4.9 software Carl Zeiss 
Balances-AG204 Mettler Toledo 
Balances-MonoBloc Mettler Toledo 
Centrifuge Thermo Fisher Scientific/Eppendorf 
Clamp Mount Micromanipulators ADInstruments 
Countess II FL Automated Cell Counter Thermo Fisher Scientific 
Digital Vortex Mixer VWR 
Fridge (4°C, -20°C, -80°C)  LIEBHERR 
Hera safe hood Thermo Fisher Scientific 
Incubator Thermo Fisher Scientific 
LAS X software Leica Microsystems 
Leica SP8X WLL upright confocal 
microscope 
Leica Microsystems 
Magnetic Hotplate Stirrer VWR 
Microliter syringe Hamilton 
Micropipette 
(10μl, 20μl, 100μl, 200μl, 1000μl) 
Eppendorf 
Microscope Axioskop 2  Carl Zeiss 
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Microscope Axiovert 25 Carl Zeiss 
Microscope camera Axiocam MRm Carl Zeiss 
Microtome Slide 2003 PFM medical AG 
Microwave Siemens 
Olympus-BX53-microscope Olympus Europe 
Perfusion system Dose IT P910  Integra Biosciences AG 
pH meter WTW Multical bench Sigma Aldrich 
Pipette boy  Eppendorf 
Shaker Biozyme Scientific 
StereoInvestigator Software 10.21.1 MicroBrightField Bioscience 
Stereotactic Frame Stereotactic Frame 
Surgical instruments Aesculap 
Vibratomes VT 1200S Leica 
Water bath Memmert 
 
2.2 Consumables 
Table 2.2 Consumables 
Product Supplier 
8-well culture slide Falcon 
Alzet Brain Infusion Kit 3 ALZET 
Alzet Osmotic Pump Model 1002 ALZET 
Cell Culture Flask (T25, T75, T150) TPP 
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Centrifuge tubes (0.5ml, 1ml, 2ml) Eppendorf 
Centrifuge tubes (15ml, 50ml) TPP / Falcon 
Cover slips Gerhard Menzel 
Culture Dish TPP / B. Braun Melsungen AG 
Culture insert (PICM03050) Millipore 
Ethibond excel (5-0) sutures Ethicon 
Microtome Blade A35 Feather 
Pap-pen Dako 
Pipette tips (10μl, 100μl, 200μl, 1000μl) Eppendorf 
Plate (6wells, 12 wells, 24 wells) TPP 
Scalpel (#15, #23) Feather 
Slide for immunolabeling Gerhard Menzel 
Stripette™ Serological Pipets  
(5ml, 10ml, 25ml) 
Corning 
Syringe (1ml, 5ml, 10ml, 50ml) B. Braun Melsungen AG 
Syringe needle (20G, 21G, 27G, 30G) B. Braun Melsungen AG 
Tissue-Tek Cryomold 
(15mm×15mm×15mm) 
Sakura Finetek 
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2.3 Cell culture materials 
Table 2.3 Cell culture materials 
Material Catalog Number Supplier 
Accutase  A6964 Sigma Aldrich 
B27 17504-044 Invitrogen 
DMEM FG0415 Biochrom 
DMEM-F12 11320-074 Invitrogen 
Fetal Bovine Serum  10270-106 Life Technologies  
hEGF 236-EG R&D systems 
hFGF 100-18B PeproTech 
MEM non-essential amino acids 11140-035 Life Technologies 
NeuroCult™ Basal Medium 5700 STEMCELL 
Technologies 
NeuroCult™ Proliferation 
Supplement 
5701 STEMCELL 
Technologies 
Penicillin-streptomycin 15140-122 Life Technologies 
Trypan Blue Solution 0.4% T8154 Sigma Aldrich 
Trypsin/EDTA L2153 Merck Millipore 
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2.4 Reagents and Chemicals 
Table 2.4 Reagents and Chemicals 
Product Supplier 
2,2,4-Trimethylpentane Thermo Fisher Scientific 
Acetone 100% Sigma Aldrich 
Agarose Sigma Aldrich 
Aqua ad iniectabilia B. Braun Melsungen AG 
Aquatex mounting medium Sigma Aldrich 
Bepanthen Bayer 
Blue Alkaline Phosphatase Substrate Kit Vector Laboratories 
Bull Serum Albumin (BSA) Sigma Aldrich 
CaCl2 · 2H2O Sigma Aldrich 
Citric acid monohydrate Sigma Aldrich 
Clodronate-Liposomes Liposoma B.V. 
Cryomatrix Thermo Fisher Scientific 
DAB-DC135c006 DCS Labline 
DAB-substrate-PC136R100 DCS Labline 
Dako Antibody Diluent Dako 
DAPI Sigma Aldrich 
DC101 Eli Lilly 
Donkey serum Jackson ImmunoResearch 
Dual Endogenous Enzyme block Dako 
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Dual Endogenous Enzyme Block Dako 
Entellan® mounting medium Merck 
Eosin G solution   Sigma Aldrich 
Ethanol 100% CLN GmbH 
Ethanol 70%  CLN GmbH 
Ethanol 96% CLN GmbH 
Ethylene glycol Sigma Aldrich 
Fluorescence Mounting Medium Dako 
Glucose 20% B. Braun Melsungen AG 
Glycerol Sigma Aldrich 
HBSS (Gibco™) Life Technologies 
HCl  Sigma Aldrich 
Horse serum (Gibco™) Life Technologies 
Hygromycin B Sigma Aldrich 
Isopropanol Sigma Aldrich 
KCl Sigma Aldrich 
Ketamin 10% Zoetis Deutschland GmbH 
KH2PO4 Sigma Aldrich 
Laminin Sigma Aldrich 
L-Glutamine (200mM, Gibco™) Life Technologies 
Lipofectamine 3000 reagent Thermo Fisher Scientific 
Mayer's Hematoxylin Solution Carl Roth 
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MEM (Gibco™) Life Technologies 
MgCl2 · 6H2O Sigma Aldrich 
Na2HPO4 · 7H2O Sigma Aldrich 
NaCl 0.9% B. Braun Melsungen AG 
NaCl Merck Millipore 
NaOH Sigma Aldrich 
NaH2PO4 · H2O Sigma Aldrich 
Paraformaldehyde (PFA) Sigma Aldrich 
PBS Apotheke Klinikum der Universität München 
PBS-Liposomes Liposoma B.V. 
pCEP4 plasmid Humanin ORF Eurofins Genomics 
Pentobarbital (Narcoren®) Merial 
Poly-D-Lysine Thermo Fisher Scientific 
Povidone iodine solution 7.5% B. Braun Melsungen AG 
Protein Block Dako 
Protein Block Serum-Free Dako 
Rompun 2% Bayer 
Roti® Histol  Carl Roth 
Sucrose Sigma Aldrich 
Sudan black B Sigma Aldrich 
Temozolomide (TMZ) Sigma Aldrich 
Tri-Natriumcitrat-Dihydrat Sigma Aldrich 
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Tris base Sigma Aldrich 
Triton X-100 Roche Diagnostics 
Tween-20 Sigma Aldrich 
WGA-594 Thermo Fisher Scientific 
 
2.5 Peptides 
Table 2.5 Peptides 
Product Catalog Number Supplier 
[Gly14]-Humanin (HNG) H54838 Designer BioScience 
(Ala13)apelin-13 (Apelin-F13A) H-7752 Bachem 
pyroglutamylated apelin-13 H-4568 Bachem 
 
2.6 Primary Antibodies 
Table 2.6 Primary Antibodies 
Immunogen Host Species Isotype Dilution Catalog number Provider 
GFP Goat IgG 1:500 R1091P Acris 
Humanin Rabbit IgG 1:100 PA1-41325 Thermo Fisher 
Iba1 Goat IgG 1:400 ab5076 Abcam 
Ki67 Rabbit IgG 1:200 ab16667 Abcam 
vWF Rabbit IgG 1:400 A0082 Dako 
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2.7 Secondary Antibodies 
Table 2.7 Secondary Antibodies 
Conjugation Antigen Host 
Species 
Dilution Catalog 
number 
Provider 
Alexa Fluor 
488 
Goat IgG Donkey 1:500 705-545-147 Jackson 
ImmunoResearch 
Alexa Fluor 
594 
Rabbit 
IgG 
Donkey 1:500 711-585-152 Jackson 
ImmunoResearch 
Alexa Fluor 
647 
Goat IgG Donkey 1:500 705-605-147 Jackson 
ImmunoResearch 
Biotinylated Goat IgG Horse 1:200 BA9500 Vector 
Laboratories 
Biotinylated Rabbit 
IgG 
Donkey 1:200 711-065-152 Jackson 
ImmunoResearch 
 
2.8 Streptavidin-conjugates 
Table 2.8 Streptavidin-conjugates 
Conjugation Dilution Catalog number Provider 
Alkaline 
phosphatase 
1:200 SA-5100 Vector 
Laboratories 
HRP 1:200 016-030-084 Jackson 
ImmunoResearch 
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3. Methods 
3.1 Animal experiments 
3.1.1 Animals 
All the animal experiments in this study were approved by the local animal care 
committee of the Government of Oberbayern and performed according to the National 
Guidelines for Animal Protection, Germany. Animals were kept in the 
Walter-Brendel-Centre of Experimental Medicine in standard cages with ad libitum 
access to water and food. All mice had a C57BL/6J background and lived in the 12-h 
light/dark cycle. During the survival monitoring, mice were checked twice a day for 
collecting the dead mice or the sick mice at a humane end-point to be sacrificed. 
 
3.1.2 Tumor implantation 
Mice were anesthetized with 7 μl/g of body weight of anesthetic comprising 1.02 ml 
10% ketamine, 0.36 ml 2% Rompun and 4.86 ml 0.9% NaCl (intraperitoneal 
injection). After anesthesia, mice were immobilized on the mouse stereotaxic 
instruments in flat-skull position and kept warm. A skin incision along the midline 
was made on the skull with a scalpel after disinfection of the skin with 7.5% povidone 
iodine solution. The cornea of both eyes were protected and kept moist with the 
Bepanthen cream. A round hole was drilled into the skull with a 21G needle tip 
according to the coordinate (1.0 mm anterior and 1.5 mm right of the bregma). Then 
1μl of glioblastoma cell (1×105, p53KOPDGFB GSCs, GFP-positive) in the 
supplement-free medium was implanted within 2 min by stereotactic injection with a 
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22G Hamilton syringe at a depth of 3 mm (the needle was inserted for 4 mm starting 
from the skull surface then retracted 1 mm). After the resting time of one minute, the 
needle was retreated at a speed of 1 mm/min. Finally, the wound was cleaned and 
confirmed no bleeding, and then the incision was sutured carefully. 
 
3.1.3 Intracerebral drug application 
One day before implantation, Alzet osmotic minipumps were prepared by filling with 
30 μg of apelin-F13A (a mutant APLNR ligand, Bachem) or 0.8 mg of DC101 
(VEGFR2-blocking antibody, as a model of ramucirumab treatment in humans, Eli 
Lilly) alone or combined for sustained delivery over 14 days (Model 1002; Alzet) in 
aCSF (artificial cerebrospinal fluid, as described by Alzet) or with aCSF alone as the 
control following priming overnight in aCSF at 37°C. The Alzet osmotic minipumps 
were implanted subcutaneously under anesthesia as previously described with the 
needle of the Alzet brain infusion kit 3 inserted into the hole originally prepared for 
orthotopic tumor implantation. 
 
 
Figure 3.1.3 Time course of the experimental procedures in the survival study. 
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3.2 Histology 
3.2.1 Perfusion and tissue preparation 
Mice were anesthetized with Narcoren® and sacrificed by perfusion through 
ventriculus sinister with 0.01 M phosphate buffered saline (PBS) followed by 
paraformaldehyde solution (PFA, 4% w/v in 0.01 M PBS) at a humane end-point in 
the survival study. After successful perfusion, brains were extracted, post-fixed in 4% 
PFA at 4°C for 48 hours, and immersed in sucrose (30% w/v in 0.01 M PBS). Then, 
brains were embedded in Cryomatrix and frozen in 2,2,4-Trimethylpentane with 
liquid nitrogen, and cut into 40-μm horizontal sections sequentially collected into a 
24-well plate filled with about 1 ml cryoprotectant (Glycerol, Ethylene glycol and 
0.01 M PB at a ratio of 1:1:2) in each well. The plates were stored in freezer (−20°C) 
and covered with aluminium foil. 
 
3.2.2 H&E staining  
To observe the tumor morphology and calculate the tumor volume, Hematoxylin and 
Eosin staining (H&E staining) was performed by the following steps: the floating 
sections were mounted on slides to air dry for 20 min; after dehydrated in 100% 
Ethanol for 30 seconds, sections were dyed in Mayer's Hematoxylin Solution for 2 
min and rinsed in running tap water for 5 min; then sections were stained in 0.5% 
Eosin solution for 30 seconds and washed shortly in distilled water; dehydration was 
performed successively in ascending Ethanol series (70% Ethanol for 1 min, 96% 
Ethanol for 1 min, 100% Ethanol for 1 min); slides were covered with Entellan® 
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mounting medium. Pictures of the H&E staining were taken by Microscope Axioskop 
2 with Axiocam MRm and Axiovision Rel. 4.9 software (Carl Zeiss). 
 
3.2.3 Quantification of tumor volume and pseudopalisading area 
Tumor volumes were obtained by measuring the area of the tumor region (marked by 
H&E staining or anti-GFP immunostaining) of every 12
th
 mouse brain section with 
Axiovision Rel. 4.9 software or ImageJ software and then calculating with the 
Cavalieri Method (i.e. estimating the tumor volume ?̂? by summing the tumor areas 
𝐴𝑖  and multiplying by the mean section cutting thickness 𝑡̅  and the section 
evaluation interval 𝑚′: ?̂? = 𝑚′ ∙ 𝑡̅  ∙ ∑ 𝐴𝑖 ) [118, 119]. The pseudopalisading area 
percentage in the tumor was estimated with ImageJ software by adjusting the 
threshold to identify the pseudopalisading necrosis. 
 
3.3 Immunofluorescence staining and quantification 
3.3.1 Immunofluorescence staining for mouse brain sections 
Floating sections were transferred from the stored 24-well plate to a 12-well plate 
washing 5 min in PBT (0.1% Tween-20 in 1× PBS) for three times. Protein blocking 
was performed 1 hour for the sections at room temperature with blocking buffer (5% 
normal donkey serum and 0.3% Triton X-100 in 1× PBS). Then sections were 
incubated overnight at 4°C in primary antibody solution. The primary antibodies used 
in this study and the corresponding dilutions were as follows: goat anti-GFP (1:500), 
rabbit anti-vWF (1:400), goat anti-iba1 (ionized calcium-binding adapter molecule 1; 
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1:400), and rabbit anti-Ki67 (1:200). On the second day, sections were incubated at 
room temperature for 2 hours with secondary antibody after washing with PBT for 
three times. The secondary antibodies were donkey anti-goat AF488 (1:500), donkey 
anti-rabbit AF594 (1:500) or donkey anti-goat AF647 (1:500). All antibodies were 
diluted in protein blocking buffer. After another round of PBT washing, nuclei were 
stained 2 min with DAPI (1:10,000). Then sections were mounted in Dako 
Fluorescent Mounting Medium after DAPI was washed away. Pictures were taken by 
the Axiovert25 microscope with Axiocam MRm and Axiovision Rel 4.8 software 
(Carl Zeiss) and quantified by ImageJ software. 
 
3.3.2 Quantification of tumor microvasculature 
A method of stereological analysis was used to quantify the microvasculature in the 
tumor area with green fluorescent tumor cells (GFP-positive) and red fluorescent 
blood vessels marked by von Willebrand factor (vWF) staining. Pictures were 
obtained by an Olympus-BX53-microscope with a motorized object table 
(MicroBrightField Bioscience). Every 12
th
 mouse brain section was examined and 
analyzed by the connected StereoInvestigator Software 10.21.1 (MicroBrightField 
Bioscience, Williston, VT, USA) using the function of space ball [120, 121]. Three 
parameters were generated after the measurement and analysis: vessel length density 
(VLD, the total vessel length per mm
3
 of tumor), vessel length (the total vessel length 
in the whole tumor), and vascular network complexity (a ratio to estimate the 
complexity of vessel branching). 
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3.3.3 Assessment of in vivo tumor cell invasiveness 
For the evaluation of the tumor cell invasiveness, three types of tumor volumes were 
determined from the GFP-stained tumor sections: 1) the overall tumor volume was 
calculated by the total tumor area including both the compact tumor regions and 
single invasive tumor cells (Cavalieri Method); 2) the compact tumor volume was 
obtained only by the area of compact tumor regions where tumor cells were in direct 
contact with each other; 3) the invasive tumor volume was calculated by subtracting 
the compact tumor volume from the overall tumor volume. And then tumor 
invasiveness was presented as the percentage of the invasive volume to the overall 
tumor volume. Photographs for the GFP-stained tumor were made by an Axiovert25 
microscope (Objective 5×) with Axiocam MRm and Axiovision Rel 4.8 software 
(Carl Zeiss). Tumor area was measured by ImageJ software. The furthest distance of 
single tumor cells migrated from the compact tumor mass was measured as well (3 
sections per mouse and 4 mice per group).  
 
3.4 In vitro experiments 
3.4.1 Cell culture 
U87MG cell line was obtained from the American Type Culture Collection (ATCC) 
and cultured under adherent conditions in DMEM containing 1× MEM non-essential 
amino acids, 1% penicillin-streptomycin (i.e. 100 units/ml penicillin, 100 µg/ml 
streptomycin), and 10% fetal bovine serum. U87 APLN-Knockdown (U87
AKD
) and 
non-silencing control cells (U87
NSC
) had been previously obtained by transduction 
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with lentiviral vectors carrying the short-hairpin RNA (shRNA) of interest [122]. 
Human glioblastoma stem cells (GSCs: NCH644, GBM14, GBM5av, GBM2 and 
GBM11) were derived from glioblastoma patients biopsies (at the Medical Faculty 
Heidelberg or at the Charité Medical University of Berlin according to local ethical 
regulations) and were maintained under stem cell cultivation conditions in 
DMEM-F12 supplemented with 1× B27, 1% penicillin-streptomycin, 10 ng/ml human 
epidermal growth factor (hEGF) and 10 ng/ml human fibroblast growth factor (hFGF) 
for NCH644, GBM14 or in Neural Stem Cell Medium (450ml) with Proliferation 
supplement (50ml), 1% penicillin-streptomycin, 10 ng/ml hEGF and 10 ng/ml hFGF 
for GBM5av, GBM2 and GBM11. GBM14
AKD
 and GBM14
NSC
 cells were obtained as 
the method for U87
AKD
 and U87
NSC
 cells [122]. 
Neural precursor cells (NPCs) had been previously isolated from the subventricular 
zone (SVZ) of the 5-day-old BL6/J mice with homozygous deletion of TP53. Isolated 
cells were cultured in spheroid conditions with DMEM-F12 medium supplemented 
with 1× B27, 1% penicillin-streptomycin, 10 ng/ml hEGF and 10 ng/ml hFGF. Mouse 
transgenic glioblastoma cells as a model of the proneural GBM subtype 
(p53
KO
PDGFB GSCs) had been previously generated by transduction of a single cell 
suspension of p53
KO
 NPCs for 1 h with a multiplicity of infection (MOI) of 80 of 
VSV-G pseudotyped GFP-PDGFB retroviral particles. Human PDGFB cDNA was 
derived from the RCAS-pBIG plasmid. Transduction efficiency was verified by GFP 
immunofluorescence and was >99% [122].  
All cells were maintained under the condition of 95% O2 and 5% CO2 humidified 
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atmosphere in a 37°C incubator. The cell counting for GBM14 proliferation in apelin 
experiments or for GBM2 and GBM11 in humanin experiments was performed by 
Countess II FL with 0.4% Trypan Blue Solution identifying the alive and dead cells at 
a dilution of 1:2. 
 
3.4.2 Wound healing assay 
U87 or GBM14 cells were seeded in the 24-well plate (3 or 5 × 10
5
 cells/well, 
respectively). After 24 hours incubation at 37°C, a scratch wound was created using a 
1,000 µl (U87) or 200 µl (GBM14) micropipette tip and cellular debris was removed. 
Then 200 nM apelin-13 or apelin-F13A was added. Pictures were taken at 0 h and 
after 10 h (U87) or 24 h (GBM14) with an Axiovert25 microscope with Axiocam 
MRm and Axiovision Rel 4.8 software (Carl Zeiss). The cell covered area was 
measured by ImageJ software. 
 
3.4.3 Fluorescent immunocytochemistry 
An 8-well culture slide (Falcon®) was coated in 37°C incubator with 50 μg/ml 
poly-D-lysine overnight followed by 5 μg/ml laminin for 2 hours. Then cells were 
plated at the concentration of 50,000 cells per well and incubated in DMEM 
containing supplements for 24 hours. Culture medium was removed subsequently, and 
cells were washed with 1× PBS once, continued with 10 min of fixation with 4% PFA 
at room temperature and 1× PBS washing for three times. After 1 hour of 
permeabilization at room temperature with blocking buffer (5% donkey serum and 0.3% 
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Triton-X in 1× PBS containing), cells were incubated with rabbit anti-Ki67 (1:200) at 
4°C overnight. On the second day, cells were washed with 1× PBS and incubated with 
the secondary antibody donkey anti-rabbit AF594 (1:500) at room temperature for 2 
hours. All antibodies were diluted in blocking solution. After three times of 1× PBS 
wash, nuclei were stained by DAPI (1:10,000) for 2min. The slides were covered by 
coverslips with Dako Fluorescent Mounting Medium. Fluorescent pictures were taken 
by Axiovert25 microscope with Axiocam MRm and Axiovision Rel 4.8 software (Carl 
Zeiss). 
 
3.4.4 Specific GFP-apelin internalization 
GBM14 cells were seeded in an 8-well culture slide (Falcon®; 10,000 cells/well) 
previously coated with 50 μg/ml poly-D-lysine in 37°C incubator overnight followed 
by 2 hours of 5 μg/ml laminin and then incubated in DMEM for 24 h. After cells 
adhered to the slide, the medium was removed and replaced by 200μl of fresh DMEM 
with 2 μM the N-terminally GFP-conjugated Apelin-13, Apelin-F13A, Apelin-13scr 
(containing the scrambled amino acid sequence of Apelin-13) or GFP-linked oligomer 
728 (positive control) continued by 120 min incubation at 37°C. In the competition 
experiment, before the addition of 2 μM GFP-apelin-13 or GFP-apelin-F13A, GBM14 
cells were incubated with 2 nM, 20 nM, 200 nM, 2 μM, or 20 μM unlabeled apelin-13 
or apelin-F13A for 30 min respectively. After all the treatments, fixation was 
performed with 4% PFA for 30 min followed by 10 min incubation of WGA-594 
1:200 (cell membrane staining) and DAPI 1:10,000 (nucleus staining) in 1× PBS at 
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room temperature. Then cells were washed with 1× PBS and the slides were covered 
by coverslips with Fluorescent Mounting Medium. Fluorescent photographs were 
taken by confocal microscope (the Leica SP8X WLL upright with the LAS X 
software) and analyzed by ImageJ software Fiji package. The quantification of the 
competition experiment was performed by measuring the number of cells containing 
GFP-conjugated peptides on the total number of cells in the picture. Six pictures were 
quantified for each condition. 
 
3.4.5 Brain slice culture procedures 
6-day old C57/BL6J mice were used to obtain the organotypic brain slice cultures 
under sterile conditions in this study. The brains were taken out after decapitation. A 
Leica vibratome was used to cut the whole brain hemispheres into 350 µm thick slices. 
Then brain slices were transferred onto the membrane (pore 0.4 µm) of a culture 
insert in the 6-well plate containing 1 ml of culture medium (25% HBSS, 44.75% 
MEM, 2 mM L-Glutamine, 25% heat inactivated horse serum, 1% 
penicillin-streptomycin, 6.5 mg/ml glucose) per well and 0.5 mg/ml 
Clodronate-liposomes (for microglia depletion) or PBS-liposomes (control). The 
slices were cultured in an incubator with 5% CO2 and humidified atmosphere at 37°C 
for 24 hours. After medium was removed, brain slices were washed with 1× PBS, 
cultured in fresh culture medium (without liposomes), and incubated for 3 days 
(waiting for microglia depletion in Clodronate-liposomes group). 0.5µl of 5,000 
glioblastoma cells (GFP-positive NCH644 and GBM5av) was inoculated into brain 
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slices by a 1µl Hamilton syringe installed in a micromanipulator. The needle was 
inserted for 200 μm deep then retracted by 50 μm. A micro pump was used to inject 
the cell suspension slowly over 1 minute. For all brain slices, the fluorescent 
glioblastoma cells were injected in the same region. Fluorescence microscopy 
photographs were made to record the area of the all tumor cells in the slices at day 0 
(immediately after injection), day 1, day 3, day 5 and day 7 by Axiovert25 microscope 
with Axiocam MRm and Axiovision Rel 4.8 software (Carl Zeiss). Photographs were 
analyzed and quantified as described in [123, 124] using ImageJ software. The 
distance between the center of the injection canal and the individual fluorescent tumor 
cells were measured, and the accumulated data were used to assemble the distance 
histograms. 
 
 
 
Figure 3.4.5 Time course of the experimental procedures in brain slice 
experiments. 
 
3.5 Immunostaining of patient specimens 
3.5.1 Immunohistochemistry (Paraffin-embedded human GBM sections) 
Paraffin-embedded sections of human GBM specimen or epilepsy non-tumor control 
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were deparaffined twice in 60°C isopropanol for 20 min. Slides were taken out for 
airdry and cool-down, and then fixed in -20°C 70% acetone for 10 min. After 1× PBS 
washing for 5 min 3 times, slides were immersed in 0.01 M citrate buffer (18ml 0.1 M 
Citric acid monohydrate and 82ml 0.1 M Tri-Natriumcitrat-Dihydrat mixed in 
distilled water; 1L, pH 6.0) and cooked with the microwave for 20 min (antigen 
retrieval). After slides cooled down, 1× PBS washing was performed for 5 min 3 
times followed by endogenous peroxidase blocking with Dako endogenous enzyme 
block for 20 min and another round of 1× PBS washing. Then sections were incubated 
30 min with Dako protein blocking reagent (protein blocking) and continued with 
rabbit anti-humanin primary antibody (1:100) overnight at 4°C. On day 2, sections 
were incubated for 2 hours with the donkey anti rabbit biotinylated secondary 
antibody (1:200) at room temperature, and then incubated for 30 min with streptavidin 
conjugated HRP (1:200) at room temperature followed by DAB incubation under the 
microscope (PBS washing performed between each steps). Then distilled water was 
used to wash away DAB and 4% PFA was applied for fixation 10 min. After this step, 
washing was changed to Tris buffer (50mM Tris base and 0.3M NaCl, pH 7.0) 5min 3 
times. Then sections were incubated for 30 min at room temperature with Dako 
protein blocking reagent continued by 4°C overnight with goat anti-iba1 primary 
antibody (1:200). On day 3, horse anti goat biotinylated secondary antibody (1:200) 
was added onto sections and incubated at room temperature for 2 hours. Then 
streptavidin conjugated alkaline phosphatase was incubated for 30 min at room 
temperature. All antibodies were diluted in Dako Antibody Diluent. Subsequantly, 
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VECTOR Blue Alkaline Phosphatase Substrate Kit incubation was performed under 
the microscope (Tris buffer washing performed between each steps). Then sections 
were washed with distilled water and the coverslips were mounted with Aquatex 
mounting medium. Photographs were made by Microscope Axioskop 2 with Axiocam 
MRm and Axiovision Rel. 4.9 software (Carl Zeiss). 
 
3.5.2 Immunofluorescence staining (Paraffin-embedded human GBM sections) 
Paraffin-embedded sections of human GBM specimen or epilepsy non-tumor control 
were deparaffined twice in 60°C isopropanol for 20 min. Slides were taken out for 
airdry and cool-down, and then fixed in -20°C 70% acetone for 10 min. After 1× PBS 
washing for 5 min 3 times, slides were immersed in citrate buffer and cooked with the 
microwave for 20 min (antigen retrieval). After slides cooled down, 1× PBS washing 
was performed for 5 min 3 times followed by protein blocking for 30 min (5% donkey 
serum and 0.3% Triton-X in 1× PBS). Then the primary antibodies rabbit 
anti-humanin (1:100) and goat anti-iba1 (1:200) was added onto section and incubated 
overnight at 4°C. On day 2, sections were incubated at room temperature with the 
secondary antibodies donkey anti rabbit AF594 (1:200) and donkey anti goat AF488 
(1:200) for 2 hours. All antibodies were diluted in blocking solution. Then sections 
were incubated for 20 min with Sudan black B solution (0.1% w/v in 70% Ethanol) to 
reduce the auto-fluorescence. DAPI 1:10,000 was used for nuclei staining (PBS 
washing performed between each steps). The slides were covered by coverslips with 
Fluorescent Mounting Medium. Fluorescence microscopy photographs were made by 
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Axiovert25 microscope with Axiocam MRm and Axiovision Rel 4.8 software (Carl 
Zeiss). 
 
3.6 Cell counting experiments 
3.6.1 Cell counting experiments for cells treated with HNG 
Cells were distributed to 5 groups: 1) culture medium with EGF&FGF and addition of 
10 mg/ml BSA (vehicle for HNG); 2) medium without EGF&FGF and addition of 
BSA; 3) medium without EGF&FGF and addition of 2 μM HNG dissolved in 10 
mg/ml BSA; 4) medium without EGF&FGF and addition of 10 μM HNG; 5) medium 
without EGF&FGF and addition of 20 μM HNG. Each condition was in triplicate. 
On day 0, cells (GBM2 and GBM11) were plated in the 6-well plate (100,000 cells 
per well) and treated with BSA or HNG. Medium were changed every 24 hours with 
BSA or HNG of the same concentration for the next 4 days. On day 7, day 14 and day 
21, the Countess II FL Automated Cell Counter was used to count the cell number of 
each well. And 100,000 cells were replated in each well for all groups with medium 
containing BSA or HNG after cell counting on day 7 and day 14. 
 
Figure 3.6.1 Cell counting experiments for cells treated with HNG. 
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3.6.2 Cell counting experiments for cells treated with HNG and TMZ 
There were 3 basic conditions: 1) culture medium with EGF&FGF and addition of 10 
mg/ml BSA (vehicle); 2) medium without EGF&FGF and addition of BSA; 3) 
medium without EGF&FGF and addition of 20 μM HNG. On each condition, cells 
were also treated with TMZ of 0 μM, 100 μM or 300 μM respectively. Each condition 
was in triplicate. 
On day 0, cells (GBM2 and GBM11) were plated in the 6-well plate (100,000 cells 
per well) and treated with BSA or HNG. Cells were treated with TMZ from day 0 to 
day2 and also treated with BSA or HNG of the same concentration every other day. 
The cell number of each well was counted by Automated Cell Counter on day 7, day 
14. And 100,000 cells were replated in each well with medium containing BSA or 
HNG of the same concentration on day 7. 
 
 
 
Figure 3.6.2 Cell counting experiments for cells treated with HNG and TMZ. 
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3.6.3 Cell counting experiments for HN overexpressing cells 
GBM2 and GBM11 cell lines were transfected with pCEP4 plasmid containing the 
humanin (HN) open reading frame and hygromycin resistance gene or transfected 
with empty vector pCEP4 plasmid containing hygromycin resistance gene by 
Lipofectamine 3000 reagent for 2 days. Then transfected cells were transferred to 
fresh culture medium and selected for 4 weeks with 400 μg/ml of hygromycin B. 
After that, the selection was maintained using 200 μg/ml of hygromycin B. 
Transfected cells (GBM2 HN, GBM2 pCEP4, GBM11 HN and GBM11 pCEP4) were 
plated in the 6-well plate (100,000 cells per well) on day 0 and treated with TMZ of 0 
μM, 100 μM or 300 μM respectively from day 0 to day 2. The cell number of each 
well was counted by Automated Cell Counter on day 7, day 14. And 100,000 cells 
were replated in each well on day 7. Each condition was in triplicate. 
 
 
 
Figure 3.6.3 Cell counting experiments for HN overexpressing cells. 
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3.7 Statistics 
Statistical analyses in this thesis were performed with the GraphPad Prism software. 
To determine statistical significance in the survival experiment, the Log-rank 
(Mantel-Cox) test was applied. For the comparison of two independent groups, the 
unpaired Student’s t-test was used. Differences among three or more groups were 
analyzed by One-way analysis of variance (one-way ANOVA) with Tukey's multiple 
comparisons test as the post hoc test. The statistical tests for each experiment are 
described in the figure legends. The criterion for the statistically significant difference 
was p < 0.05. 
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4. Results 
4.1 Targeting apelin/APLNR reduces angiogenesis and tumor cell invasiveness in 
glioblastoma 
4.1.1 Combination treatment targeting VEGFR2 and apelin/APLNR 
synergistically improves survival of glioblastoma-bearing mice 
In animal models, systemic administration of VEGFR2-blocking antibody DC101 was 
shown to suppress the growth of various tumors, including glioblastoma (GBM) [125]. 
However, Kunkel et al. reported a side effect of DC101 with significant increase of 
tumor invasion (small satellite tumors) in addition to the inhibition of tumor growth 
and angiogenesis in a glioblastoma mouse model (intracerebral G55 xenografts, G55 
is a human GBM cell line) [59]. Recently, our laboratory found that targeting 
apelin/APLNR by apelin-F13A (a mutant ligand for APLNR) decreased the tumor 
invasiveness in human primary GBM mouse models as well as transgenic mouse 
models (p53
KO
PDGFB GSCs, generated from mouse neural precursor cells with TP53 
deletion and PDGFB overexpression; see Figure 5 in [122]). Also, one of the major 
suspected causes of the failure of anti-angiogenic treatment for glioblastoma by 
targeting VEGF/VEGFR2 signaling is the upregulation of alternative angiogenic 
factors. A previous study from our research group demonstrated that apelin/APLNR 
signaling plays an essential role in angiogenesis during embryonic development as 
well as in GBM pathology [56]. Hence, in the present study, I investigated whether 
the combination of anti-VEGFR2 therapy and targeting of apelin/APLNR signaling 
can achieve a better outcome than anti-VEGFR2 treatment alone. The p53
KO
PDGFB 
58 
 
GSCs were orthotopically implanted in C57 BL6/J mice and allowed to expand for 7 
days. Mice were divided into four groups and treated intracerebrally with apelin-F13A 
(n = 9), anti-VEGFR2 antibody (DC101; n = 7), apelin-F13A and anti-VEGFR2 
antibody (n = 7), or with vehicle (artificial cerebrospinal fluid, aCSF) alone as a 
control (n = 10). 
The median survival in the control group (aCSF treated mice) was 52 days. In the 
group of DC101 administration, the median survival increased to 67 days that was 28% 
longer than the control mice (p = 0.0145). A similar increase of median survival was 
achieved in apelin-F13A treated mice (63 days; 21% increase; p = 0.0139) in 
comparison with control mice. Notably, the mice with DC101 and apelin-F13A 
coadministration showed a significant increase in the survival (86 days; 65% increase 
vs. control mice; p = 0.0016). And the median survival of the co-treated group was 
also significantly longer compared with the administration of apelin-F13A (p = 
0.0327) or DC101 (p = 0.0385) alone (Figure 4.1.1). 
59 
 
 
Figure 4.1.1 Survival of C57 BL6/J mice bearing p53
KO
PDGFB GSCs. Mice were 
intracerebrally treated with vehicle (artificial cerebrospinal fluid, aCSF; n = 10), 
anti-VEGFR2 antibody (DC101, n = 7), apelin-F13A (a mutant ligand for APLNR,  
n = 9), or apelin-F13A combined with DC101 (n = 7) respectively. The median 
survival of DC101, apelin-F13A and the coadministration group significantly 
increased to 67 days (p = 0.0145), 63 days (p = 0.0139) and 86 days (p = 0.0016) 
respectively compared to the aCSF group (52 days). Log-rank (Mantel-Cox) test was 
used to determine statistical significance, *p < 0.05, **p < 0.005 compared to aCSF 
control group. 
 
4.1.2 Tumor morphology and tumor volume in the survival study 
In order to investigate histopathological changes in the experimental groups that 
might explain differences in survival, brains were collected from mice sacrificed at 
humane end-point. In all groups, big tumor masses were observed in the corpus 
striatum and cortex of the right hemisphere. The cerebral midline shifted to the left 
because of the extending tumor mass and single invading tumor cells were found in 
the left brain hemisphere of some animals. The tumors of the four treatment groups 
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showed typical glioblastoma morphology [6] (Figure 4.1.2a) characterized by large 
areas with high cell density, hyperangiogenesis with malformed blood vessels 
(examples shown as asterisks in Figure 4.1.2a A’&B’), local bleeding (arrows, Figure 
4.1.2a A’, the color of erythrocytes) and necrotic foci (cross, Figure 4.1.2a C’&D’), 
which were accompanied by pseudopalisades (white lines, Figure 4.1.2a C’). In the 
tumor necrotic foci (cross, Figure 4.1.2a C’), cell death with pyknotic nuclei 
(arrowhead) was surrounded by pseudopalisades (white lines).  
The tumor volume calculated after Hematoxylin and Eosin staining (H&E staining) is 
shown in Figure 4.1.2b A. Because all the tumors were collected after the 
tumor-bearing animals entered the terminal stage and had to be sacrificed at humane 
end-point, there was a similar median of the tumor volume in aCSF control (142.5 
mm
3
), DC101 (138 mm
3
), apelin-F13A (136.3 mm
3
) and apelin-F13A + DC101 group 
(133.5 mm
3
). However, these volumes were reached at different time points: 50 days 
in aCSF, 67 days in DC101, 62 days in apelin-F13A and 86 days in apelin-F13A + 
DC101 group (Figure 4.1.2b B). Two or three mice of every group showed a small 
tumor which might be due to the invasive glioblastoma cells growing into the 
ventricle and possibly blocking the circulation of CSF before a big tumor mass could 
be formed in the brain parenchyma. 
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Figure 4.1.2a Tumor morphology at experimental end-point. (A-D) Hematoxylin 
and Eosin staining (H&E staining) shows examples of a big tumor on brain sections 
from four treatment groups. All tumors showed large area of dense cells with darkly 
stained nuclei, hyperangiogenesis with malformed blood vessels and bleeding area, 
and necrotic foci accompanied by pseudopalisades. No obvious difference of these 
morphological features was found among groups in H&E staining. (A’) In the 
close-up image of aCSF control tumor, asterisks and arrows indicate the example of 
malformed blood vessels and bleeding respectively; (B’) In the close-up image of 
DC101 treated tumor, asterisks indicate the example of blood vessels in the tumor. (C’) 
Picture in higher magnification of apelin-F13A treated tumor shows the tumor 
necrotic foci (cross), dead cells with pyknotic nuclei (arrowhead), and 
pseudopalisading area (white lines). (D’) Higher magnification images of apelin-F13A 
plus DC101 treated tumor show the tumor necrotic foci (cross), dead cells with 
pyknotic nuclei (arrowhead).  
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Figure 4.1.2b Tumor volume and survival time at experimental end-point. (A) 
Tumor volume of each mouse was estimated from the tumor area in H&E staining. 
The medians of the tumor volume (arrow) in four groups were: 142.5 mm
3
 in aCSF, 
138 mm
3 
in DC101, 136.3 mm
3 
in apelin-F13A and 133.5 mm
3
 in apelin-F13A + 
DC101 group. No significant difference of tumor volume was found among groups 
assessed by Kruskal-Wallis test (p = 0.954). (B) Individual survival time for all 
samples. The survival time of mouse with a median tumor volume (arrow) was: 50 
days in aCSF, 67 days in DC101, 62 days in apelin-F13A and 86 days in apelin-F13A 
+ DC101 group. 
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4.1.3 Pseudopalisading area of the tumor 
Pseudopalisades were observed in the H&E staining of murine p53
KO
PDGFB GBM. 
To investigate whether there are differences in pseudopalisades in different treated 
groups, I quantified the pseudopalisades in tumors by measuring the percentage of 
pseudopalisading area over the total tumor area in H&E images (3 mice with 
comparable tumor size from each group). No significant difference of pseudopalisades 
was found in different treated tumors. The pseudopalisading area percentage was 
around 55% in all groups (Figure 4.1.3 A). I also investigated pseudopalisades of 
GBM specimens from patients before and after bevacizumab treatment. Likewise, no 
significant difference of pseudopalisades was detected in the GBM tissue before and 
after bevacizumab treatment (Figure 4.1.3 B). 
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Figure 4.1.3 The extent of pseudopalisades is unchanged in murine p53
KO
PDGFB 
GBM and human GBM specimens after different treatments. (A) 
Histopathological calculation of pseudopalisades in murine tumors at humane 
end-point. Asterisks indicate the pseudopalisading areas. Arrows indicate the necrotic 
foci surrounded by pseudopalisades. The image in the top right illustrates procedures 
for measuring the pseudopalisading area. Values are reported as the mean ± SEM 
(standard error of the mean). One-way ANOVA was used to determine statistical 
significance (p = 0.893). (B) H&E pictures and quantification of pseudopalisades in 
GBM specimens from patients pre- and post-bevacizumab treatment. Asterisks 
indicate the pseudopalisades. Values are reported as the mean ± SEM. Student’s t-test 
was used to determine statistical significance (p = 0.226). 
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4.1.4 Apelin-F13A and DC101 inhibit tumor angiogenesis in murine glioblastoma 
An Olympus-BX53-microscope with the connected StereoInvestigator Software 
(MicroBrightField Bioscience, Williston, VT, USA) was used to analyze the tumor 
angiogenesis in murine glioblastoma. Sections with comparable tumor size were 
stained for von Willebrand factor (vWF) to identify vessels. By using the function of 
space ball, three parameters were generated after the measurement and analysis: 
vessel length density (VLD, the total vessel length per mm
3
 of tumor), vessel length 
(the total vessel length in the whole tumor), and vascular network complexity (a ratio 
to estimate the complexity of vessel branching) [120, 121]. After DC101 treatment, 
the VLD markedly decreased to 440 mm/mm
3
 compared to 613 mm/mm
3
 in controls 
(p = 0.035). Similarly, apelin-F13A treatment significantly decreased VLD to 357 
mm/mm
3
 (p = 0.004). Coadministration of DC101 and apelin-F13A further reduced 
VLD to 243 mm/mm
3
 (p = 0.003), which was also much lower than that in 
DC101-treated tumors (p = 0.033; Figure 4.1.4 B). Similar results were found by 
assessing vascular network complexity (Figure 4.1.4 C). Total vessel length of the 
tumor also decreased remarkably in the apelin-F13A treated group and apelin-F13A + 
DC101 coadministration group as compared to controls (Figure 4.1.4 D). These data 
indicate that administration of DC101 or apelin-F13A alone can significantly suppress 
angiogenesis in glioma mouse models. Most importantly, combined administration of 
DC101 and apelin-F13A improved antiangiogenesis over all other experimental 
groups in this preclinical model. 
66 
 
 
 
Figure 4.1.4 Tumor microvasculature at experimental end-point. (A) 
Immunofluorescence staining of von Willebrand factor (vWF) shows the vessels in 
the tumor of the four treatment groups. (B) Quantification of vessel length density 
(VLD) in the tumor area by stereomorphology (n = 4 per group). The VLD decreased 
significantly in DC101 (p = 0.035), apelin-F13A (p = 0.004) and apelin-F13A + 
DC101 group (p = 0.003) compared to aCSF controls. Also, the VLD in the 
apelin-F13A + DC101 group was significantly lower than that in DC101-treated 
tumors (p = 0.033). (C) The vascular network complexity was remarkably lower in 
DC101 (p = 0.003), apelin-F13A (p = 0.001) and apelin-F13A + DC101 group (p = 
0.0005) than that in controls. The vascular network complexity in apelin-F13A + 
DC101 group was also significantly lower than that in DC101 group (p = 0.033). (D) 
The total vessel length decreased dramatically in the apelin-F13A group (p = 0.04) 
and apelin-F13A + DC101 group (p = 0.028) in comparison to aCSF controls. Values 
are reported as the mean ± SEM. Student’s t-test was used to determine statistical 
significance, *p < 0.05, **p < 0.005, ***p < 0.0005. 
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4.1.5 VEGFR2-blockade increases but apelin-F13A decreases the invasiveness of 
glioblastoma cells 
Next, GBM cell invasiveness was investigated in the p53
KO
PDGFB GBM models. 
The p53
KO
PDGFB GSCs (including the single invasive tumor cells) could be 
identified on histological brain sections by green fluorescent protein (GFP) expression 
and immunostaining for GFP, which facilitates the analysis of glioblastoma cell 
invasiveness. The tumor invasiveness was determined as the percentage of invasive 
tumor volume over the total tumor volume (invasive tumor volume plus compact 
tumor volume, Figure 4.1.5 C&D). Tumors with comparable size were analyzed. 
Invasiveness was inspected at 10× and 20× objectives and invasive area was 
measured on composite images of lower (5× objective) magnification. In the 
composite pictures, the blue line indicates the compact tumor border and the red line 
indicates the invasive tumor front (Figure 4.1.5 A). The invasive glioblastoma volume 
was 30% in control tumors. Administration of DC101 alone (as expected; [59]) had a 
pro-invasive effect. The invasive volume significantly increased to 55% in DC101 
treated tumors. On the contrary, an anti-invasive effect was found in apelin-F13A 
treatment which reduced the invasive glioblastoma volume robustly to 8%. The 
percentage of invasive volume in mice co-treated with DC101 and apelin-F13A (18%) 
was between that in the DC101 treated group (55%) and apelin-F13A treated group 
(8%; Figure 4.1.5 B). The invasion trajectories from the dense tumor core were also 
quantified by measuring the distance of single tumor cells migrated away from the 
compact tumor mass. Similar results were found for the invasive distance (Figure 
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4.1.5 E). In the close-up photographs, the differences of invasiveness could be 
observed more clearly: massive invasion of single cells was visible in DC101 treated 
tumors; however, only a few individual cells invaded into the peritumoral brain tissue 
in apelin-F13A treated tumors (Figure 4.1.5 A). These results suggest that 
apelin/APLNR targeting has an anti-invasive effect on glioblastoma cells, decreasing 
the pathological side effects of established anti-angiogenic regimen such as 
anti-VEGFR2 therapy, offering one potential mechanism that explains improved 
survival after apelin-F13A coadministration in our preclinical study. 
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Figure 4.1.5 The invasiveness of glioblastoma cells at experimental end-point. (A) 
The upper panel gives an overview on tumors (composite images of 5× objective) 
with gliomas visualized by immunostaining for GFP. The blue line indicates the 
compact tumor border and the red line indicates the invasive tumor front. The lower 
panel shows higher magnification images of the compact tumor border (arrowhead) 
and invasive tumor cells (arrow). (B) Quantification of the percentage of the invasive 
tumor volume over the total tumor volume. The percentage of invasive tumor volume 
increased significantly in DC101 treated tumors (55%, n = 4, p = 0.037) but decreased 
remarkably in apelin-F13A treated tumors (8%, n = 4, p = 0.014) compared to aCSF 
controls (30%, n = 5). The percentage of invasive tumor volume in apelin-F13A + 
DC101 treated group (18%, n = 4) was between that in DC101 treated group and 
apelin-F13A treated group. (C) Quantification of the total tumor volume of the four 
treatment groups. No significant difference of the total tumor volume was found 
among groups. (D) Quantification of the compact tumor volume in the four 
experimental groups. There was a significant difference of the compact tumor volume 
between control and apelin-F13A treated group (p = 0.029). (E) The distance of 
invasion trajectories from the dense tumor core (3 sections per mouse and 4 mice per 
group). The invasive distance increased to 1.78 mm in DC101 group (p = 0.04) but 
decreased to 0.28 mm in apelin-F13A group (p = 0.001) compared to 1.10 mm in 
controls. The invasive distance in apelin-F13A + DC101 treated group was 0.65 mm. 
Values are reported as the mean ± SEM. Student’s t-test was used to determine 
statistical significance, *p < 0.05, **p < 0.005, ***p < 0.005. 
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4.1.6 The APLNR ligand apelin-F13A reduces the number of iba1 positive cells in 
p53
KO
PDGFB GBM 
The immune state in the glioblastoma may be different after various treatments in the 
survival experiment and may also affect the tumor growth or glioblastoma cell 
migration and invasion. Microglia are the major innate immune cells in the CNS. 
Therefore, I quantified the tumor-associated myeloid cells in the tumor area marked 
by ionized calcium-binding adapter molecule 1 (iba1) staining [126, 127], and found 
that the number of iba1 positive cells in apelin-F13A treated group was less than that 
in other groups (Figure 4.1.6). In consideration of the pro-invasive and pro-angiogenic 
effect of glioblastoma-associated microglia/macrophage as reported by previous 
studies [123, 128-130], we hypothesize that there may be some interactions of 
apelin/APLNR signaling (glioblastoma cell) and tumor-associated 
microglia/macrophage in terms of glioblastoma cell invasiveness and angiogenesis, 
which warrants further investigation. 
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Figure 4.1.6 Iba1 positive cells in gliomas at experimental end-point. (A) 
Representative photographs of iba1 positive cells in the tumor area of four groups. (B) 
Quantification of iba1 staining in the tumor area. The number of iba1 positive cells in 
apelin-F13A group was significantly lower than aCSF (p = 0.002), DC101 (p = 0.003), 
and apelin-F13A + DC101 group (p = 0.03). Values are reported as the mean ± SEM 
(3 mice per group). Student’s t-test was used to determine statistical significance, *p < 
0.05, **p < 0.005. 
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4.2 The relationship of apelin/APLNR signaling and glioblastoma invasiveness 
4.2.1 The APLNR ligand apelin-13 and apelin-F13A both inhibit tumor cell 
migration in a wound healing assay 
To study the direct impact of apelin on APLNR expressing GBM cells, I performed a 
wound healing assay by using two cell lines (U87
 
and GBM14) of which the 
relatively high levels of apelin expression had been knocked down [122] (U87
AKD
 and 
GBM14
AKD
; with the non-silencing control cells as control, NSC). The tumor cell 
migration was assessed for 24 hours because the GBM14 cells (which grow as 
spheres) would detach from the culture-plate at later time-points. For U87 cells, the 
gap area would be completely closed by the migrating cells after 24 hours. Therefore, 
the cell covered area for U87 cells was measured 10 hours after the gap was formed. I 
found that the cell covered area increased faster in apelin knockdown cells compared 
to that in the non-silencing control cells for both cell lines, indicating that the 
invasiveness of glioblastoma cells increased significantly after endogenous apelin 
knockdown. Moreover, the increased migration in apelin knockdown cells could be 
diminished by exogenous addition of apelin-13 or apelin-F13A (Figure 4.2.1), which 
supports my finding that the invasiveness of glioblastoma cells in vivo could be 
inhibited by the stimulation of APLNR on glioblastoma cells with apelin-F13A. 
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Figure 4.2.1 Glioblastoma cell migration in a wound healing assay. (A) 
Representative pictures for U87 cells and GBM14 cells are shown. The quantification 
of cell migration was performed by measuring the cell-covered area 10 hours (U87) or 
24 hours (GBM14) after the gap was induced. The red lines indicate the edge of tumor 
cells at the starting time point. (B) Quantification of glioblastoma cell migration. 
Compared to apelin knockdown U87 (U87
AKD
) control group, the cell covered area 
increased more slowly in U87
NSC
 control group (NSC: non-silencing control; p = 
0.003), U87
AKD
 apelin-13 group (p = 0.009), and U87
AKD
 apelin-F13A group (p = 
0.009). Compared to GBM14
AKD
 control group, the slower cell migration reached 
significance in GBM14
NSC
 control group (p = 0.01) and GBM14
AKD
 apelin-F13A 
group (p = 0.005), and reached marginal significance in GBM14
AKD
 apelin-13 group 
(p = 0.05). Values obtained from three independent experiments are reported as the 
mean ± SEM. Student’s t-test was used to determine statistical significance, *p < 0.05, 
**p < 0.005. 
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4.2.2 The invasiveness of glioblastoma cells in brain slices increases after apelin 
knockdown 
In another approach to investigate apelin-modulated glioblastoma cell-invasion, I 
inoculated human primary glioblastoma cells (NCH644 and GBM5av) into murine 
orthotopic brain slice culture (Figure 4.2.2 A, F). The invasiveness of glioblastoma 
cells within organotypic brain slice cultures was measured by determining the number 
of single invasive cells migrating a certain distance away from the injection site 
(Figure 4.2.2 B). The quantified data were presented as the cell percentage 
distribution of the migration distances. The migration distance at day 7 for GBM5av 
showed that a significantly higher percentage of apelin depleted GBM5av
AKD
 cells 
reached farther migration distance compared to control GBM5av
NSC
 cells with 
migration radii > 900 μm (Figure 4.2.2 E). Significant difference were also observed 
when comparing the NCH644
AKD
 cells and NCH644
NSC
 cells (Figure 4.2.2 G), which 
demonstrates again that glioblastoma cells without the endogenous apelin stimulation 
become more invasive. 
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Figure 4.2.2 The invasiveness of glioblastoma cells in the brain slice increases 
after apelin knockdown. (A) Representative microscopy image for GBM5av
NSC
 and 
76 
 
GBM5av
AKD 
tumor cells in the brain slice on day 0, day 1, day 3, day 5 and day 7. (B) 
An example shows the method of measuring the migrating distance of single invasive 
cells from the injection site. (C, D) The close-up images show the single invasive 
GBM5av
NSC
 (C) and GBM5av
AKD 
cells (D) in the brain slice. Arrows indicate the 
invasive cells. (E) Cell percentage distribution histogram of the migrating distances 
for GBM5av
NSC
 and GBM5av
AKD 
tumor cells in brain slices. There was a significant 
difference between two groups in the distance of 1000-1400 μm. (F) Representative 
microscopy image for NCH644
NSC
 and NCH644
AKD 
tumor cells in the brain slice on 
day 0, day 1, day 3, day 5 and day 7. (G). Cell percentage distribution histogram of 
the migrating distances for NCH644
NSC
 and NCH644
AKD 
tumor cells in brain slices. 
There was a significant difference between two groups in the distance of 1100 μm and 
1200 μm. 5-7 brain slices per group were used for the quantification. Values are 
reported as the mean ± SEM. Student’s t-test was used to determine statistical 
significance, *p < 0.05. 
 
4.2.3 The increased cell invasiveness in apelin knockdown GBM cells is lost upon 
microglia depletion 
Microglia can be efficiently eliminated in brain slice cultures by administration of 
clodronate-liposomes (using PBS-liposomes as control) [123]. With this method, we 
could further explore the relationship of apelin/APLNR signaling and microglia in 
tumor invasiveness. Apelin knockdown cells and non-silencing control cells of 
GBM5av or NCH644 were inoculated in the microglia-depleted brain slice 
respectively and the invasion of glioblastoma was determined as mentioned above. 
Interestingly, no difference of invasiveness was found between apelin knockdown 
cells and non-silencing control cells after microglia were depleted in the brain slice 
(Figure 4.2.3 B, F). These findings suggest that microglia in the brain slice is required 
for the increase of invasiveness in the apelin knockdown cells (here GBM5av
AKD
 and 
NCH644
AKD
). By comparing the invasiveness of apelin knockdown GBM cells in 
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microglia-intact and microglia-depleted brain slices, we found that these cells were 
more invasive in microglia-intact brain slices (Figure 4.2.3 C, G). Therefore, the 
pro-invasive effect of tumor-associated myeloid cells (also reported by previous 
studies [123, 128]) was not influenced by apelin knockdown in GBM cells. 
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Figure 4.2.3 Increased cell invasiveness in apelin knockdown GBM cells is lost 
upon microglia depletion. (A) Representative microscopy image for GBM5av
NSC
 
and GBM5av
AKD 
tumor cells in microglia-depleted brain slice on day 0, day 1, day 3, 
day 5 and day 7. (B) Cell percentage distribution histogram of the migrating distances 
for GBM5av
NSC
 and GBM5av
AKD 
tumor cells in microglia-depleted brain slices. No 
significant difference was found between two groups. (C) Cell percentage distribution 
histogram of the migrating distances for GBM5av
AKD
 cells in microglia-intact and 
microglia-depleted brain slices. There was a significant difference between two 
groups in the distance of 1100-1300 μm. (D) Iba1 staining for brain slices verified the 
efficiency of microglia depletion after clodronate-liposomes treatment. (E) 
Representative microscopy image for NCH644
NSC
 and NCH644
AKD 
tumor cells in 
microglia-depleted brain slice on day 0, day 1, day 3, day 5 and day 7. (F) Cell 
percentage distribution histogram of the migrating distances for NCH644
NSC
 and 
NCH644
AKD 
tumor cells in microglia-depleted brain slices. No significant difference 
was found between two groups. (G) Cell percentage distribution histogram of the 
migrating distances for NCH644
AKD
 cells in microglia-intact and microglia-depleted 
brain slices. There was a significant difference between two groups in the distance of 
1100 μm. 6-8 brain slices per group were used for the quantification. Values are 
reported as the mean ± SEM. Student’s t-test was used to determine statistical 
significance. 
 
4.2.4 The proliferation in apelin knockdown GBM14 cells is unchanged 
compared to non-silencing control GBM14 cells 
To exclude the possibility that the increase of invasion in apelin knockdown cells was 
a result of enhanced in vitro proliferation after endogenous apelin depletion, I checked 
the cell proliferation of GBM14
NSC
 and GBM14
AKD 
cells. Thus, 100,000 cells of 
GBM14
NSC
 or GBM14
AKD
 were plated on day 0 and the cell numbers were counted 
on day 7 and day 14. The cell numbers did not show a difference between GBM14
NSC
 
and GBM14
AKD 
(Figure 4.2.4 A). In addition, to assess the proliferative state of 
GBM14
NSC
 and GBM14
AKD 
cells, the Ki67 status [131] was examined by 
immunofluorescence staining in 40× objective for both cell lines in vitro as well as in 
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vivo in the tumor area (the mouse brain tumor tissue was obtained from my colleague 
Mengzhuo Hou’s previous experiments). Similarly, no significant difference was 
detected (Figure 4.2.4 B, C). 
 
Figure 4.2.4 Cell proliferation of GBM14
NSC
 and GBM14
AKD
 in vitro and in vivo. 
(A) Proliferation examined by cell counting for GBM14
NSC
 and GBM14
AKD
 cells in 
vitro. 100,000 cells of GBM14
NSC
 or GBM14
AKD
 were plated on day 0 and the cell 
numbers were counted on day 7 and day 14 by Countess II FL with 0.4% Trypan Blue 
Solution identifying the alive and dead cells at a dilution of 1:2. 100,000 cells were 
replated after the cell counting on day 7. Three independent experiments were 
performed in triplicate. Values are reported as the mean ± SEM. Student’s t-test was 
used to determine statistical significance. No significant difference was found 
between two groups. (B) Representative photographs and quantification of Ki67 
staining for GBM14
NSC
 and GBM14
AKD
 cells in vitro. Nine pictures were used to 
quantify the percentage of Ki67 positive cells. Values are reported as the mean ± SEM. 
Student’s t-test was used to determine statistical significance. No significant 
difference was found between two groups. (C) Representative pictures and 
quantification of Ki67 staining for GBM14
NSC
 or GBM14
AKD
 tumor in APLN gene 
wild-type (APLN
WT
) or APLN gene knockout (APLN
KO
) mouse brain (tissue from my 
colleague’s previous experiments, the number of Ki67 positive cells per field in the 
tumor area was quantified for 3 mice per group). Values are reported as the mean ± 
SEM. One-way ANOVA was used to determine statistical significance. No significant 
difference was found among groups. 
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4.2.5 Apelin peptides activate GPCR internalization on APLNR expressing GBM 
cells 
G-protein coupled receptors (GPCRs) get internalized upon ligand binding for signal 
desensitization [132]. To follow apelin-binding, apelin peptides were linked to a 
GFP-tag in the N-terminus (obtained from Sören Reinhard and Prof. Ernst Wagner, 
Department of Pharmacy, LMU Munich, Germany). I administered GFP-linked apelin 
peptides to GBM14 cells and found that both apelin-13 and apelin-F13A were 
internalized by GBM14 cells, while a scrambled apelin-13scr peptide (containing the 
scrambled amino acid sequence of Apelin-13) was not (Figure 4.2.5 A), which 
suggests that both apelin-13 and apelin-F13A can bind to APLNR and cause the 
internalization of the APLNR. Additionally, the specificity of peptide uptake was 
confirmed by a dose escalated competition assay with unlabeled peptide. The 
internalization of GFP-labeled apelin-13 and apelin-F13A was competitively blocked 
by unlabeled apelin-13 and apelin-F13A respectively, and the level of inhibition 
increased as the concentration of unlabeled peptides went higher (Figure 4.2.5 B). 
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Figure 4.2.5 Specific internalization of GFP-labeled apelin-13 and GFP-labeled 
apelin-F13A by GBM14 cells. (A) Confocal microscopy images show the 
internalization of GFP-linked cationic lipo-oligomer 728 (unspecific positive control), 
GFP-Apelin-13 and GFP-Apelin-F13A, but no internalization of GFP-Apelin-13scr. 
The cell membrane and nuclei were stained by wheat germ agglutinin (WGA-Alexa 
Fluor 594) in red and DAPI in blue respectively. The arrows indicate the internalized 
GFP-labeled peptides. (B) Competitive inhibition of GFP-labeled apelin-13 or 
apelin-F13A (2 μM) uptake by unlabeled apelin-13 or apelin-F13A (2 nM, 20 nM, 
200 nM, 2 μM, or 20 μM). The quantification was performed by measuring the 
number of cells containing GFP-conjugated peptides on the total number of cells in 
the picture. Six pictures were quantified for each condition. Values are reported as the 
mean ± SEM. 
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4.3 Microglia-associated peptide Humanin protects glioblastoma cells from stress 
4.3.1 Humanin expression in human GBM specimens 
In this second part of my thesis, I investigated another peptide humanin (HN) that our 
research group identified to be overexpressed in microglia from GBM patients. To 
study the local expression of HN in GBM, I examined paraffin-embedded human 
GBM sections by immunohistochemistry and immunofluorescence staining. Figure 
4.3.1 A shows the single staining of the HN (brown) or iba1 (blue) in GBM tissue. 
Figure 4.3.1 B shows the double staining of the HN (brown) and iba1 (blue) in GBM 
tissue and tumor-free epilepsy tissue. The brown arrow indicates HN positive cells, 
the blue arrow indicates iba1 positive microglia/macrophage, and the red arrow points 
to the double stained cell in the picture of immunohistochemistry (Figure 4.3.1 B). 
Quantification showed that both HN positive cells and iba1 positive cells in the GBM 
tissue (n = 11 patients) were significantly more than those in tumor-free tissue (n = 5 
patients). Moreover, about half the HN positive cells were also iba1 positive (Figure 
4.3.1 C). In the immunofluorescence staining, the red cells are HN positive cells and 
the green cells are iba1 positive cells. GBM tissue showed more co-localization of 
iba1 and HN than tumor-free tissue (Figure 4.3.1 D). These results of staining indicate 
that HN is highly expressed in GBM compared to tumor-free tissue and that microglia 
could be the major source of HN in the microenvironment of GBM. 
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Figure 4.3.1 Humanin expression in human GBM specimens. (A) 
Immunohistochemistry for humanin (brown) or iba1 (blue) single staining in GBM 
tissue. (B) Immunohistochemistry for humanin and iba1 double staining in GBM 
tissue and tumor-free epilepsy tissue. The brown, blue, and red arrows indicate 
humanin positive cells, iba1 positive myeloid cells, and the double stained cells 
respectively. (C) The number of humanin positive, iba1 positive and double positive 
cells in GBM tissue (n = 11 patients) was significantly higher than in tumor-free 
tissue (n = 5 patients). Values are reported as the mean ± SEM. Student’s t-test was 
used to determine statistical significance, *p < 0.05. (D) Co-immunofluorescence 
staining of humanin and iba1 for GBM tissue and tumor-free tissue. Most of the 
iba1-positive cells in GBM tissue were also humanin positive (arrows). In the 
tumor-free tissue, some iba1-positive but humanin-negative cells (arrowheads) were 
also found besides the double positive cells (arrows).  
 
4.3.2 The cytoprotective effect of HNG for glioblastoma cells under growth 
factor-deprived conditions in vitro 
The immunostaining showed high expression of HN in GBM; hence we asked if HN 
plays an important role in GBM. To test whether HN has a cytoprotective effect on 
tumor cells, I looked at two primary GBM cell cultures (GBM2 and GBM11) under 
stress condition. Towards this aim, cells were cultured in medium deprived for human 
epidermal growth factor (hEGF) and human fibroblast growth factor (hFGF; stress 
conditioned medium) and treated with a potent HN analogue (S14G HN or HNG, 
replacing serine at position 14 with glycine) [106, 133]. I found a dose dependent 
protective effect of HNG on GBM cells in EGF and FGF deprived medium (Figure 
4.3.2 A, E). On day 7, the cell number in 2 μM HNG group was similar to that in 
growth factor-deprived control. However, in the groups treated with higher HNG 
concentrations (10 μM and 20 μM), cell numbers were significantly higher than that 
in growth factor-deprived control (Figure 4.3.2 B, F). In the first week, cells were 
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treated with HNG every day from day 0 to day 4. In the second and third week, cells 
were only treated with HNG on day 7 and day 14. I found that the protective effect of 
HNG decreased in the second week and disappeared on day 21 (Figure 4.3.2 D, H), 
implying that the rescued GBM cell growth under stress was largely depended on the 
continuous HNG support. 
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Figure 4.3.2 The cytoprotective effect of HNG for glioblastoma cells in growth 
factor-deprived condition. (A) Cell proliferation curves of GBM2 in different 
conditions. (B-D) Quantification of the cell counting for GBM2 in different conditions 
on day 7 (B), day 14 (C) and day 21 (D). (E) Cell proliferation curves of GBM11 in 
different conditions. (F-H) Quantification of the cell counting for GBM11 in different 
conditions on day 7 (F), day 14 (G) and day 21 (H). For the two cell lines, a dose 
dependent protective effect of HNG (a potent humanin analogue, replacing serine at 
position 14 with glycine) was found. On day 7, the cell number in 10 μM and 20 μM 
HNG group was significantly higher than in growth factor-deprived control group. 
Values are reported as the mean ± SEM. One-way ANOVA followed by Tukey's 
multiple comparisons test was used to determine statistical significance, *p < 0.05 
compared to BSA with EGF&FGF, 
#
p < 0.05 compared to BSA without EGF&FGF. 
 
4.3.3 HNG protects glioblastoma cells from a chemotherapeutic agent 
temozolomide 
To further investigate the cytoprotective effect of HNG for GBM cells, we created 
another clinically relevant stress condition for tumor cells by adding temozolomide 
(TMZ, an alkylating agent inducing the death of tumor cells by breaking the DNA 
double-strand) to the culture medium besides the stress of growth factors deprivation. 
20 μM HNG was applied every other day in this experiment and the concentration of 
TMZ were applied at 0 μM, 100 μM and 300 μM. For both primary GBM cultures 
(GBM2 and GBM11) tested, the cell number of HNG treated cells in growth 
factor-deprived medium was similar to that of complete medium at every 
corresponding concentration of TMZ, but significantly higher than that of growth 
factor-deprived control at every corresponding concentration of TMZ (Figure 4.3.3). 
This indicates that HNG has a protective effect on GBM cells even under two types of 
stress (TMZ and growth factor deprivation). More specifically, in growth 
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factor-deprived culture condition, the cell number of HNG and 100 μM TMZ treated 
group was markedly higher than that of BSA treated control group on day 14 for both 
cell lines. The effect disappeared when the concentration of TMZ increased to 300 
μM (Figure 4.3.3 B, D). These results demonstrate that HNG can protect glioblastoma 
cells from TMZ treatment in vitro (at least in 100 μM condition). 
 
 
Figure 4.3.3 The cytoprotective effect of HNG for glioblastoma cells under 
treatment with temozolomide. (A, B) Quantification of GBM2 cells counted on day 
7 and day 14 in different conditions. (C, D) Quantification of GBM11 cells counted 
on day 7 and day 14 in different conditions. For both cell lines, the cell number of 
HNG treated group and control group with complete medium was significantly higher 
than that of growth factor-deprived control group at every corresponding 
concentration of temozolomide (TMZ). Values are reported as the mean ± SEM. 
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One-way ANOVA followed by Tukey's multiple comparisons test was used to 
determine statistical significance, *p < 0.05 compared to BSA with EGF&FGF or 
HNG treatment at the corresponding concentration of TMZ, 
#
p < 0.05 compared to 
BSA without EGF&FGF. 
 
4.3.4 Humanin overexpression in the GBM cell fails to induce a cytoprotective 
effect 
With the purpose of answering the question if the cytoprotective effect of HN can also 
be conferred by intracellular HN, I overexpressed HN in GBM2 and GBM11 cell by 
transfecting the cells with a plasmid containing the HN open reading frame (HN ORF) 
or an empty plasmid (pCEP4) as a control. Then both HN overexpressing cells and 
control cells were cultured in growth factor-deprived medium or complete medium 
additionally treated with TMZ at 0 μM, 100 μM and 300 μM respectively. Cell 
numbers were counted on day 7 and day 14 in all conditions. The dose dependent 
cytotoxic effect of TMZ was evident as the cell number decreased proportional to 
TMZ increase. The positive effect of EGF/FGF was observed as well when comparing 
the growth factor-deprived medium and complete medium conditions. However, the 
number of HN overexpressing cells and control cells in the corresponding medium 
was not different in all conditions (0 μM, 100 μM or 300 μM TMZ) (Figure 4.3.4), 
suggesting that HN overexpression inside the GBM cell cannot induce the 
cytoprotective effect. 
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Figure 4.3.4 Overexpression of humanin in GBM2 and GBM11 fails to induce 
cytoprotective effects. (A, B) Quantification of cell numbers of HN overexpressing 
GBM2 cells (GBM2 HN) and control GBM2 cells (GBM2 pCEP4, an empty plasmid) 
counted on day 7 and day 14 in different conditions. (C, D) Quantification of GBM11 
HN and GBM11 pCEP4 cell numbers counted on day 7 and day 14 in different 
conditions. No significant difference was found between HN overexpressing cells and 
control cells in the corresponding medium in all conditions (0 μM, 100 μM or 300 μM 
TMZ). Values are reported as the mean ± SEM. Student’s t-test was used to determine 
statistical significance when comparing HN overexpressing cells and control cells in 
the same condition (for example, HN overexpressing cells vs. pCEP4 control cells in 
medium without EGF&FGF and treated with 100 μM TMZ). 
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5. Discussion 
In the first part of my scientific project, I investigated the role of apelin/APLNR 
signaling in tumor angiogenesis and GBM cell invasiveness in an in vivo survival 
experiment, in an in vitro wound healing assay and in brain slice culture experiments. 
In the second part, I also investigated the effect of microglia-derived peptide humanin  
on the growth of primary GBM cell cultures. 
 
5.1 Targeting apelin/APLNR inhibits both tumor angiogenesis and tumor cell 
invasion in glioblastoma 
The p53
KO
PDGFB GSCs that we used in the survival experiment generated a tumor in 
the mouse brain with typical glioblastoma morphology as assessed by histology. The 
cells were generated from mouse neural precursor cells (NPCs) with TP53 deletion 
and PDGFB overexpression representing the proneural subtype of GBM [21]. Tumor 
volumes determined by H&E staining showed a comparable median volume in all 
four experimental groups because all the brains in the survival experiment were 
collected after the tumor-bearing mice entered the terminal stage and had to be 
sacrificed at humane end-point. Most of the mice had a big tumor in the brain, but a 
few mice in each group displayed a smaller tumor. One possible explanation is that 
the injection points in these mice are too close to the lateral ventricle, allowing tumor 
cells to grow into the ventricle early and block the circulation of cerebrospinal fluid 
before a large tumor mass can be formed. 
Targeting apelin/APLNR signaling by apelin-F13A (a mutant ligand for APLNR) in 
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this glioblastoma mouse model prolonged the survival of animals compared to control 
treatment (aCSF, artificial cerebrospinal fluid). Coadministration of apelin-F13A and 
DC101 (anti-VEGFR2 antibody) further improved the survival when compared to 
mice with each single treatment. These effects probably result from the combined 
inhibition of tumor angiogenesis by apelin-F13A and DC101 and the anti-invasive 
effect of apelin-F13A. By examining the tumor on brain sections, we verified that 
blood vessel length density in the tumor area decreased after the treatment of 
apelin-F13A or DC101. And the vessel length density reached the lowest level in the 
combined treatment group. These results suggest that apelin/APLNR signaling indeed 
participates in the tumor angiogenesis of glioblastoma, and that apelin-F13A can 
enhance the repression of neoangiogenesis in DC101 treated tumor and may have 
synergistic effects with VEGFR2 inhibitors in antiangiogenesis. 
On the other hand, we revealed a previously undiscovered role of apelin/APLNR 
signaling pathway in the invasiveness of glioblastoma cells. Although both 
apelin-F13A and DC101 can diminish tumor angiogenesis, their action on tumor cell 
invasion seems to be divergent. The glioblastoma cells became more invasive after the 
treatment of DC101, which is consistent with the previous findings that 
anti-VEGF/VEGFR therapy increases glioma cell invasion [53-55, 59]. Interestingly, 
apelin-F13A, on the contrary, inhibited the invasiveness of glioblastoma cells in 
comparison with aCSF controls. Moreover, apelin-F13A also counteracted the 
invasion-promoting adverse effect of DC101 in the APLNR and VEGFR2 
co-targeting group. Hence, the anti-invasive effect of apelin-F13A may also be a 
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factor contributing to increased survival of apelin-F13A treated mice. 
In line with the in vivo findings, my in vitro experiments provide additional evidence 
for the important role of apelin/APLNR signaling in the invasiveness of glioblastoma 
cells. By knocking down apelin in glioblastoma cells, we could investigate the 
function of tumor cell-derived apelin. The wound healing assay and brain slice 
experiment both showed an increase of cell migration/invasion after apelin 
knockdown in glioblastoma cells. Interestingly, the increased tumor cell migration of 
apelin knockdown cells was abolished after exogenous administration of apelin-13 or 
apelin-F13A in wound healing assays. Although a recent publication suggested that 
the apelin/APLNR signaling pathway plays a critical role in GSC maintenance [134], 
we did not find any difference in proliferation between apelin knockdown and 
non-silencing control cells examined by cell counting and Ki67 status, which rules out 
the possibility that the increased tumor cell invasion results from altered proliferation 
rates. Furthermore, APLNR belongs to G-protein coupled receptor family and APLNR 
internalization experiments confirmed the binding and uptake specificity of the 
apelin-13 and apelin-F13A by the glioblastoma cells. 
Additional gene knockdown and knockout experiments performed previously by our 
research group [122] showed as well that apelin knockdown in the tumor cells or 
apelin knockout in the mice reduced the glioblastoma angiogenesis. Nevertheless, 
apelin knockdown in tumor cells or knockout in host mice increased the glioblastoma 
cell invasion [122], which implies that the apelin/APLNR signaling may have 
dichotomous roles in tumor angiogenesis and invasiveness in GBM. Taken together, 
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we speculate that apelin-F13A administrated in the survival experiment, on the one 
hand, modulates APLNR on glioblastoma cells to decrease tumor invasion; on the 
other hand, counteracts intratumoral apelin ligands, which can activate APLNR on 
endothelial cells and vascular sprouting. This could be supported by the 
pharmacological properties of apelin-F13A which is a partial agonist for APLNR with 
lower receptor binding capacity [72, 75] and a competitive agonist for natural APLNR 
ligands [75]. 
The extend of pseudopalisades in the p53
KO
PDGFB GBM was not altered after 
administrated APNLR or VEGFR2 blocking, but the apelin mRNA expression in 
pseudopalisades decreased strongly and significantly within DC101-treated tumor 
(see Figure 1 in [122]). Therefore, the blocking of VEGFA/VEGFR2 signaling 
pathway by the anti-VEGFR2 antibody can reduce the apelin expression in 
glioblastoma and reduced VEGFR2-activation as well as apelin levels blunt glioma 
angiogenesis, but reduced apelin expression also disinhibits GBM cell invasion. 
An important advantage of our novel GBM model (p53
KO
PDGFB GSCs) is that we 
can investigate the immune compartment in fully immune competent mice. As 
microglia are the prime immune cells of the brain, I also analyzed the iba1 positive 
microglia/macrophages in the tumor area of this GBM model. Here I observed that the 
number of microglia/macrophages was reduced in apelin-F13A treated tumor in 
comparison to the controls. In brain slice experiments, the increased cell invasiveness 
in apelin knockdown GBM cells (compared to non-silencing control cells) is lost upon 
microglia depletion. These findings suggest that there may be some interactions of 
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apelin/APLNR signaling and tumor-associated microglia/macrophage in terms of 
glioblastoma cell invasiveness, which warrants further investigation. 
A good approach to improve the treatment outcomes is the genetic stratification of 
glioblastoma, as different genetic subtypes may respond differently to one therapy. 
Recent studies have proposed that the proneural or classical subtypes of glioblastoma 
have a better therapeutic response to anti-VEGFA treatment [63, 64]. High apelin 
expression was also linked to angiogenesis only in the proneural or classical subtypes 
by gene ontology analysis, but not in mesenchymal glioblastoma [122]. Our research 
group previously found that apelin knockout in the host decreased tumor angiogenesis 
and increased tumor invasion in classical GBM mouse models [122]. The mouse cell 
line p53
KO
PDGFB GSC was used in this study to establish a model of human 
proneural-subtype glioblastoma [21]. The cell lines used for in vitro experiments are 
also proneural subtype (GBM14, NCH644) or classical subtype (GBM5av). Thus, the 
results of DC101 and apelin-F13A treatment in the mouse model hint that targeting 
VEGFA/VEGFR2 together with apelin/APLNR signaling pathway may be a new 
strategy to improve the treatment of the proneural and classical glioblastoma 
subtypes. 
 
5.2 Microglia-derived humanin acts as a protective factor for glioblastoma cells 
Another factor important in the communication of GBM cells with microglia might be 
the microglia expressed gene humanin (HN). We have found the peptide HN to be 
strongly overexpressed in glioblastoma-associated myeloid cells by comparing the 
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expression profile of myeloid cells in glioblastoma and the tumor-free brain 
(unpublished data by our laboratory). In the second part of this thesis, I thus 
investigated the role of HN in glioblastoma. I first examined the expression of HN in 
the GBM patient specimens by immunostaining and verified the high expression of 
HN in GBM. Co-staining of HN and iba1 indicated that microglia may be the main 
cell type that expresses HN in GBM. 
In consideration of the cytoprotective effect of HN reported by previous studies [106, 
107, 114], the effect of HNG (a potent HN analogue [106, 133]) on two primary 
human glioblastoma cell lines was studied in vitro. Two types of stress on the cell 
culture were created by growth factor (hEGF and hFGF) deprivation and 
temozolomide (TMZ) addition respectively. I found that HNG can rescue 
glioblastoma cells from growth factor-deprived culture condition in a dose dependent 
manner and can also protect these cells from the cytotoxicity of TMZ. Hence, these 
results suggest that the highly expressed HN in GBM could be cytoprotective for 
tumor cells and support tumor growth. One possibility is that this cytoprotective effect 
is induced by HN from outside of tumor cells through the activation of receptors on 
the plasma membrane. Another possibility is that HN exerts anti-apoptotic effects 
inside the cells by binding to pro-apoptotic protein Bax or IGFBP-3. I tested this by 
overexpressing HN in GBM cells, and I did not find the rescue effect of intracellular 
HN under the stress of growth factors deprivation and TMZ, which suggests that HN 
may not protect the glioblastoma cells through intracellular interactions in our model. 
One question that needs to be answered for this experiment is the confirmation of the 
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overexpression of HN in GBM cells by quantitative PCR (qPCR), RNA sequencing or 
western blot, which could not be finalized within the time-frame of this dissertation 
project. Even so, HN was probably overexpressed in GBM cells, which were 
transfected with a plasmid containing HN open reading frame and hygromycin 
B-resistance gene. Therefore, only the successfully transfected cells in which HN and 
hygromycin B-resistance gene were expressed would survive after a long period of 
selection with hygromycin B. 
As a preliminary study, the results of in vitro experiments are promising. Potential 
plasma-membrane receptors for HN have been reported in previous studies [114-117]. 
The first is N-formyl peptide receptors (FPRs) that are related to the activation of 
ERK1/2 signaling pathway [114]. The second is a tripartite receptor 
CNTFR/WSX-1/gp130 which activates the STAT3 signaling pathway [117]. As HN 
acts from outside but not inside of glioblastoma cells, the specific receptor of HN is a 
crucial aspect for this project and the expression level of HN receptors on GBM cells 
can be tested by qPCR and western blot. The concentration of the HNG used for in 
vitro experiments was unphysiologically high (20 μM). Therefore, the HN receptor 
expression level may be exceedingly low when the cells are cultured in vitro or the 
two primary human GBM cell lines used in this study may consistently be low 
expressing cell lines for HN receptor. Identification of GBM cells with high HN 
receptor expression level and continuation with pharmacological experiments using 
HN as an agonist can show if HN receptor expression levels determine HN-sensitivity. 
Once the HN receptor and HN-activated signaling pathway which underlie the 
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cytoprotective effect for GBM cells are thoroughly investigated, inhibitors for 
blocking the HN receptor and associated signaling pathway can be used to establish 
new pre-clinical GBM treatments and may improve the survival of GBM patients. 
In conclusion, I investigated here short peptide signaling molecules like apelin and 
HN, which have not been given sufficient attention so far. The pro-angiogenic role of 
apelin in GBM was confirmed, and a previously unknown function of the 
apelin/APLNR signaling in glioma invasion was uncovered in this study. We also 
revealed and described for the first time (to the best of my knowledge) a 
cytoprotective effect of microglia-derived peptide HN on GBM cells. All these 
findings are conducive to the development of new GBM therapies. 
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6. Summary 
The tumor microenvironment plays an essential role in supporting tumor growth. In 
this thesis, I focused on the interaction of tumor cells with the newly forming 
vasculature and the tumor-associated myeloid cells. In this context, I specifically 
investigated two potential treatment targets in the tumor microenvironment of 
glioblastoma (GBM). First, I studied the role of apelin/APLNR signaling in GBM. 
Apelin/APLNR signaling is a pathway that is required for angiogenesis to take place 
and has been found to be upregulated in GBM. Therefore, I hypothesized that 
blocking APLNR may improve the effect of anti-angiogenic therapy for GBM. In a 
survival study using an immunocompetent, orthotopic transgenic glioma model 
(p53
KO
PDGFB-GBM cells), I found that targeting apelin/APLNR signaling by the 
mutant APLNR ligand apelin-F13A prolonged the survival of GBM mice. 
Interestingly, apelin-F13A acted synergistically together with anti-VEFGR2 antibody 
therapy and prolonged survival of GBM mice even longer when compared to the 
single compound-treated mice. Here, apelin-F13A significantly reduced tumor 
angiogenesis and blunted the increased invasiveness caused by anti-VEGFR2 
treatment. This demonstrated that there is a previously undiscovered role of 
apelin/APLNR signaling in controlling glioma invasiveness. Consistent with this, 
apelin knockdown GBM cells showed a significant increase of invasiveness in an in 
vitro wound healing assay and in ex vivo brain slice experiments that I performed next. 
The pro-invasive effect of the reduction of apelin expression was attenuated by 
application of exogenous apelin-F13A. All these results suggest that apelin/APLNR 
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signaling plays dichotomous roles in tumor angiogenesis and GBM invasiveness: 
apelin promotes GBM angiogenesis and simultaneously blunts GBM invasion. The 
synthetic APLNR ligand apelin-F13A in turn exerts therapeutic effects by blocking 
GBM invasion as well as reducing tumor neoangiogenesis. 
Glioblastoma-associated myeloid cells are also an important component in the tumor 
microenvironment promoting tumor growth. In the second part of my thesis, I studied 
the cytoprotective peptide humanin (HN). HN was found to be more abundantly 
expressed in glioblastoma-associated microglia/macrophages than in control 
microglia (from brain tissue of epilepsy patients). In my thesis, I found in addition, 
that HN expression was higher in GBM specimens than in tumor-free brain tissue as 
examined by immunostaining. In vitro, HNG (a potent HN analogue added to the 
culture medium) had a protective effect on glioblastoma cells maintained under 
cell-stress conditions, such as growth factors deprivation. In my experiments, HNG 
did also protect glioblastoma cells from the GBM chemotherapeutic temozolomide. 
Overexpression of HN inside the tumor cells, however, failed to induce the 
cytoprotective effect, suggesting that HN probably acts by receptors on the cell 
membrane rather than by cell endogenous (cytoplasmic) effects. Hence, 
microglia-expressed HN could be a tumor-supportive factor in the tumor 
microenvironment and may play an important role in the resistance to temozolomide 
in some GBM patients. Thus, blockage of the protumorigenic action of HN could be a 
possible strategy for adjuvant GBM therapy that deserves further investigations. 
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Zusammenfassung 
Das Mikromilieu des Tumors ist ausschlaggebend für sein Wachstum sowie die 
Entwicklung von neuen Mikrogefäßen und tumorassoziierten myeloiden Zellen. In 
dieser Doktorarbeit stelle ich meine wissenschaftliche Arbeit vor welche die 
Untersuchung von zwei möglichen Behandlungsmethoden im Bereich des 
Mikromilieus des Glioblastoms (GBM) umfasst. In erster Linie habe ich die Rolle des 
Apelin/APLNR-Signalweges in Glioblastomen untersucht. Der 
Apelin/APLNR-Signalweg ist wichtig für die Angiogenese und es hat sich gezeigt, 
dass Apelin und sein Rezeptor APLNR in Glioblastomen hochreguliert werden. 
Deshalb stellte ich die Hypothese auf, dass die Blockade des Apelin Rezeptors 
(APLNR) die Wirkung der anti-angiogenen Therapie verbessern könnte. In einer 
Überlebenszeitanalyse in der wir immunkompetente, orthotope transgene 
Gliommodelle (p53
KO
PDGFB-GBM Zellen) verwendet haben, konnte ich 
herausfinden, dass die Unterdrückung des Apelin/APLNR-Signalweges durch den 
mutierten APLNR Liganden Apelin-F13A die Überlebenszeit der GBM tragenden 
Mäuse verlängert. Interessanterweise beobachtete ich einen synergistischen Effekt 
von Apelin-F13A bei gleichzeitiger Therapie mit dem anti-VEGFR2 Antikörper und 
zwar verlängerte sich die Überlebenszeit der GBM Mäuse noch mehr im Vergleich zu 
den Mäusen die nur eine der beiden Behandlungen erhalten hatten. Apelin-F13A 
reduzierte die Tumorangiogenese signifikant und schwächte den Anstieg der 
Invasivität des Tumorwachstums ab, der von der anti-VEGFR2 Therapie verursacht 
wurde. Dies zeigt, dass der Apelin/APLNR-Signalweg in der Kontrolle der Invasivität 
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der Gliome eine zuvor unentdeckte Rolle spielt. Im Ergänzend dazu habe ich 
Wundheilungsexperimente in vitro und Experimente mit Hirnschnitten ex vivo 
durchgeführt, in welchen Apelin knock-down GBM Zellen eine signifikante 
Steigerung der Invasivität aufwiesen. Der proinvasive Effekt des Verlustes von Apelin 
wurde durch die Zugabe von exogenem Apelin-F13A abgeschwächt. Diese Ergebnisse 
weisen darauf hin, dass der Apelin/APLNR-Signalweg in zweierlei Hinsicht eine 
Rolle für die Tumorangiogenese und die GBM Invasivität spielt: Apelin fördert die 
Glioblastom-assoziierte Angiogenese und schwächt gleichzeitig das invasive 
Wachstum des Glioblastoms ab. Der synthetische APLNR Ligand Apelin-F13A 
wiederum übt seine therapeutische Wirkung aus indem er die GBM Invasivität 
blockiert und die Neoangiogenese vermindert. 
Ein weiterer wichtiger Bestandteil des Mikromilieus des Tumors sind 
Glioblastom-assoziierte myeloide Zellen die das Tumorwachstum unterstützen. Im 
zweiten Teil meiner Doktorarbeit habe ich mich mit dem zytoprotektiven Peptid 
Humanin (HN) befasst. In meinen Untersuchungen konnte ich eine höhere 
Humanin-Expression in Glioblastom-assoziierten Mikroglia/Makrophagen 
nachweisen im Vergleich zu Mikrogliazellen die aus dem Hirngewebe von 
Epilepsie-Patienten stammten und als Negativkontrolle dienten. Zusätzlich konnte ich 
mit den im Rahmen meiner Doktorarbeit durchgeführten immunhistochemischen 
Färbungen zeigen, dass die HN-Expression in GBM Gewebeproben höher ist als in 
tumorfreien Hirngewebeproben. HNG, ein wirksames HN-Analogon welches dem 
Zellkulturmedium hinzugefügt wurde, zeigte einen zytoprotektiven Effekt bei 
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Glioblastomzellen die Zellstress ausgesetzt wurden (Entzug der Wachstumsfaktoren). 
In weiteren Experimenten konnte dieser zytoprotektive Effekt auch bei 
Glioblastomzellen die mit dem GBM Chemotherapeutikum Temozolomid behandelt 
wurden beobachtet werden. Weiterhin zeigte sich dieser zytoprotektive Effekt jedoch 
nicht bei Tumorzellen die eine endogene Überexpression von HN aufwiesen, was 
darauf hinweisen könnte, dass HN über Zellrezeptoren auf der Zellmembran wirksam 
wird und nicht über einen endogene zytoplasmatischen Signalweg. Daher scheint es 
möglich, dass die HN-Expression in den Mikroglia tumorsupportiv wirkt und einer 
der Gründe für die Temozolomid-Resistenz mancher GBM-Patienten sein könnte. 
Daraus schließe ich, dass die Blockade dieser protumorigenen Wirkung von HN eine 
mögliche zusätzliche therapeutische Strategie gegen GBM darstellen könnte und 
weitere Untersuchungen in diese Richtung wichtig sind. 
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